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general IntroductIon
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1.1 the vulva 
During embryogenesis, the external genitalia develop under the influence of 
hormones. The vulva originates from the genital tubercle (clitoris), urogenital groove 
(vestibulum), urethral folds (labia minora) and genital swellings (labia majora).1 
Structures belonging to the vulva are the mons pubis, labia majora and minora, the 
vestibule of the vagina, the hymen, the clitoris and the external urethral orifice. The 
outer aspects of the vulva are covered with normal cornified skin epithelium, which 
consists of three layers; the epidermis, dermis and subcutis. The epidermis of labia 
majora, labia minora and the frenulum of the clitoris is cornified stratified squamous 
epithelium and is developed from the embryonic ectoderm. It is histologically 
made up of four layers: the stratum germinativum or basal layer that forms the 
boundary with the dermis, the stratum spinosum, the stratum granulosum, and 
the stratum corneum (Fig. 1). The vestibule is lined with mucosal epithelium of 
endodermal origin, as is the vagina. The vaginal epithelium, however, is derived from 
the embryonic mesoderm.2,3 The transition of cornified epithelium to non-cornified 
mucous epithelium can be seen in some patients as the Hart’s line. The skin functions 
as a barrier to protect women from harmful external influences, which is particularly 
important in the genital area because of exposure to a wide range of bacteria, fungi 
and viruses. Cells that reside in the skin are keratinocytes, melanocytes, Merkel cells 
and Langerhans cells (LCs).3,4 The latter is an important resident of the epidermis; it 
is a bone marrow-derived dendritic cell which plays an essential role in the immune 
surveillance of the skin.5
Figure 1. Section of vulvar skin.
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1 1.2 Immune response
The role of the immune system is to protect us from potential dangerous microorganisms 
such as viruses and bacteria. The immune response is a complex interaction between 
cells, cytokines, chemokines and other soluble proteins. All these players have their 
own specific role, which is essential for an effective defense against infection. 
1.2.1 Innate immune response
The innate immune response is the fast first line defense against an invading 
pathogen. It is a non-specific reaction initiated immediately after the first exposure to 
a microorganism. Soluble factors (e.g. complement molecules) and multiple immune 
cells are involved. These immune cells, like natural killer cells (NKs), mast cells, 
eosinophils, basophils, macrophages, neutrophils and dendritic cells (DCs) identify 
and eliminate pathogens that might cause infection. Additionally, they produce 
cytokines and chemokines that act together to recruit more immune cells to the site 
of infection.6 
Of critical importance are the DCs, which are antigen-presenting cells (APCs) and 
the key regulators of the immune system. Different functional subsets exist; immature 
or mature myeloid DCs (mDCs) and plasmacytoid DCs (pDCs).5,7 As mentioned before, 
Langerhans cells are the DCs that reside in the epidermis.5 
Immature mDCs are responsible for the first recognition of antigens by toll-like 
receptors (TLRs) at their cell surface. TLRs recognize pathogen-associated molecular 
patterns (PAMPs), which are specific molecular structures conserved within a class 
of microbes.8 After antigen-binding, the DC matures, expressing molecules that 
will lead to binding and stimulation of T cells, and migrates under the influence of 
chemokines to draining lymph nodes. Here they present antigens on their cell surface 
(bound to major histocompatibility complex (MHC)) to naive T cells. In this way, they 
can activate naive T cells, which is a crucial step in activating the adaptive immune 
response.5 pDCs are less potent in their capacity to activate T cells than mDCs. They 
play a role in the defense against viral infections by producing large amounts of 
interferon-α (IFNα), which inhibits viral replication and stimulates cytotoxicity of 
macrophages and NK cells.7,9 
In conclusion, the innate immune system responds to pathogens in a generic way 
and provides immediate defense against infection. Although it does not result in 
long-lasting immunity, it is able to induce the adaptive immune response.
1.2.2 adaptive immune response
The adaptive immune response, in which T cells play a central role, regulates the 
destruction of infected cells and generates immune memory. It is a slow response, 
but highly specific.10 As mentioned above, DCs can activate the adaptive immune 
response by presenting antigens to naive T cells in the draining lymph nodes. Binding 
to naive T cells will result in production of memory and effector T cells, such as T 
helper type 1 (Th1), Th2 and Th17 CD4+ T cells, CD8+ cytotoxic T cells, or regulatory 
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T cells (Treg cells). Activation of naive T cells by DCs is a complex interaction, and 
co-stimulatory signals are needed for an adequate activation. Cytokines produced by 
the DC provide the co-stimulatory signal that dictates whether the T-cell will take the 
Th1, Th2, Th17 or regulatory path (Fig. 2). Which kind of cytokines are produced, is 
in turn influenced by the response made by the innate immune system when it first 
recognizes the pathogen.7,10-12 
The different effector T cells have a variety of functions and produce specific 
cytokines. CD8+ cytotoxic T cells recognize virus-infected cells and kill them. Th1 
CD4+ T cells secrete IFNγ and promote the activation of macrophages, NK cells and 
cytotoxic CD8+ T cells, hereby generating cell-mediated immunity. Th2 and Th1 
CD4+ cells coordinate the activation of B cells and production of different classes of 
antibodies, thus generating a humoral response. Th17 CD4+ T cells enhance the acute 
inflammatory response by recruiting neutrophils to the site of infection. Finally, Treg 
cells are essential for controlling the immune response by production of inhibitory 
cytokines and are therefore important in preventing autoimmunity.10
In summary, the immune response is an intricate interplay between cells, cytokines, 
and chemokines, which is essential for protecting us from harmful pathogens. 
However, it can result in opposite effects when functions or interactions between 
players are disturbed, and in that case immune responses can potentially harm us. 
Hence, it is not surprising that disturbance of the immune response can result in a 
variety of diseases as discussed in the next paragraphs.
1.3 vulvar IntraepIthelIal neoplasIa
Vulvar intraepithelial neoplasia (VIN) is a vulvar skin disease with a malignant potential, 
which has increased in incidence over the last few decades affecting more and more 
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Figure 2. T-helper cell differentiation (modified from Tato and O’Shea, Nature 200611). 
Driven by different types of cytokines produced by dendrite cells (DC), undifferentiated T helper cells can develop into Th1, Th2, Th17 or Treg 
cells, which all have their own specific cytokine profile and function.  
 
 
Figure 2. T-helper cell differentiation (modified from Tato and O’Shea, Nature 200611). Driven by dif-
ferent types of cytokines produced by dendrite cells (DC), undifferentiated T helper cells can develop 
into Th1, Th2, Th17 or Treg c lls, which all have their own specific cytokine profile and function.
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young women.13-17 In the past, various terms for VIN have been used, but in 2004 
the terminology was revised. Since then, VIN can be divided in two subtypes: usual	
type VIN (uVIN), which is caused by a persistent infection with a high-risk type human 
papillomavirus (hrHPV), and differentiated	type VIN (dVIN), which is associated with 
lichen sclerosus (LS) and lichen planus (LP).18,19 Both subtypes differ in etiology, 
morphology, malignant potential, and consequently are treated differently. 
1.3.1 usual type vulvar intraepithelial neoplasia
uVIN is the most common subtype and it predominantly occurs in younger women 
with a peak incidence around 40 years of age.16,20,21 Symptoms are pruritus and pain, 
but lesions can also be asymptomatic.22,23 Typically, uVIN lesions are multifocal.20,22,23 
Accurate vulvar inspection during routine gynecologic examination is important for 
diagnosis, and to confirm diagnosis a biopsy of the most suspicious part of the lesion 
is required.24
HPV plays an important role in the etiology of uVIN, it can be found in 72-100% 
of VIN lesions, and in most cases HPV16 is detected.21,25-29 Approximately 80% of all 
sexually active, female adolescents are at least once during their life-time infected 
with HPV.30 When an hrHPV infection persists, a premalignant lesion, such as uVIN 
can develop.31-33 If untreated, 9% of lesions will progress to invasive cancer within 
1-8 years.23
Treatment of uVIN is a challenge, primarily because of its location, multifocality 
and tendency to recur.34,35 Therefore, various treatments have been used in the past. 
For a long time, surgery was the treatment of choice.35 However, since recurrence 
rates and psychosexual impact of mutilating surgery are high,36-40 a trend towards 
more conservative treatments has been observed in recent years. These medical 
treatments, such as application with the immune response modifier imiquimod, 
or vaccination with therapeutic HPV vaccines, aim to enhance patients’ immune 
response, and thereby treat the underlying cause of uVIN: a persistent infection with 
hrHPV.41-47
Topical treatments for uVIN are attractive because they can be applied by 
the patient and usually preserve the anatomy of the vulva. Imiquimod is an 
imidazoquinoline and its activity is mediated through stimulation of cells involved 
with the innate immune response including monocytes, macrophages and DCs.48 
Imiquimod binds to TLR 7 and 8 on DCs, which leads to activation of nuclear factor-
kappa B (NF-κB). This activation results in secretion of multiple cytokines, including 
tumor necrosis factor alpha (TNFa), interleukin (IL)-12, IL-2, IL-6, G-CSF, GM-CSF, 
IFNγ, IFNa, IL-23, IL17A and IL-17F, as well as the chemokines IL-8 and monocyte-
chemoattractant protein (MCP)-1 (Fig. 3).48-50 Mouse studies showed that the IL-23/
IL-17 axis is critical for imiquimod-induced skin inflammation.50 The production of 
proinflammatory cytokines and chemokines results in an influx of immune cells to 
the site of application, in particular pDCs that produce high amount of IFNa, and 
in migration of LCs into the draining lymph nodes leading to increased antigen 
presentation.48,49 Many of the cytokines induced by imiquimod can enhance adaptive 
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immune responses, in particular Th1 production of IFNγ and other cell-mediated 
immune responses (e.g. Th17) that are important in the control of viruses, tumors, 
and intracellular pathogens. Besides TLR-dependent effects, imiquimod can also 
interfere with adenosine receptor signaling, hereby impairing an important negative 
feedback regulation that normally limits inflammatory responses, thus resulting in 
augmentation of the inflammatory response.51 
Taken together, imiquimod is a potent immune activator and therefore the 
effectiveness of imiquimod was investigated in HPV-related disorders, as genital 
warts, uVIN and vaginal intraepithelial neoplasia (VAIN).42,43,52-54 From the results 
of 17 studies on the efficacy of imiquimod treatment for VIN (210 patients in 1 
randomized controlled trial (RCT), 10 case series and 6 case reports), 26-100% had 
a complete response to imiquimod, and 0-60% a partial response, while treatment 
duration ranged from 3 to 32 weeks.43 Our department of Obstetrics and Gynecology 
also conducted an RCT and found a complete response to imiquimod therapy in 
35% of patients and a partial response (a reduction in lesion size of >25%) in an 
additional 46% of patients. All complete responders were still disease-free at one 
year of follow-up.42 
Figure 3.
Imiquimod
TLR 7 / 8
DENDRITIC CELL
cytokines & chemokines
NF-κB
NF-κB
Cellular immune response
Figure 3. Imiquimod: mode of action. This figure is a simplified overview of the working mechanism 
of Imiquimod. It binds to Toll-like receptor (TLR) 7 and 8 on dendritic cells, which induces consecutive 
activation of nuclear factor-kappa B (NF-κB). This activation leads to secretion of multiple cytokines 
and chemokines, resulting in a profound cellular immune response.
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Recently, other immunomodifying treatments for uVIN as therapeutic 
vaccination against HPV or a combination of vaccination and imiquimod have 
been reported.46,55 Complete response rate after vaccination with long-peptides of 
HPV16 viral oncoproteins E6 and E7 was 47% (9 of 19 women) and this response 
rate was maintained at 24 months of follow-up.46 However, although results of 
immunomodifying treatments for uVIN are promising, long-term efficacy and 
recurrence rates are still unknown.42,43,46,55
1.3.2 differentiated vulvar intraepithelial neoplasia
dVIN is very rare, <2-5% of all VIN lesions are of this type.16,56 In contrast to uVIN, 
dVIN is not related to HPV, it is often found on a background of LS and is usually 
found in older women.20 The clinical and histological diagnosis of dVIN is a challenge. 
Patients are often symptomatic with a long-lasting history of LS or LP-related 
symptoms of vulvar itching and/or burning.57 In particular in patients with LS or LP, 
one has to be aware of dVIN in case of unifocal red lesions, areas with hyperkeratosis, 
ulceration or a rough and irregular surface.20,57 However dVIN is mostly diagnosed 
in correlation with invasive squamous cell carcinoma (SCC), which is possibly due to 
the high malignant potential and the short intraepithelial phase of dVIN.57,58 Because 
of its high malignant potential, the preferred treatment is radical surgical excision.56 
1.4 lIchen sclerosus
LS is a chronic inflammatory skin disease that most frequently affects the anogenital 
area.59  LS has a bimodal peak in incidence, it occurs mainly in elder women with a 
mean age of onset between the fifth and sixth decade, but it is also diagnosed in 
prepubertal girls.60 Although various genetic-, autoimmune-, infectious- and local 
factors have been proposed to be involved in the etiology of LS, the exact cause is 
still unknown.24,59-60 An autoimmunological basis of the disease is strongly suggested 
by studies describing the association of LS with HLA class II antigen DQ7.61,62 An 
association was also observed between LS and autoimmune diseases, which showed 
that between 21.5 and 34% of all LS patients have an autoimmune disease and 21 to 
74% of all patients have autoantibodies.63-66 In addition, presence of autoantibodies 
against extra cellular matrix protein 1 and basement membrane zone (BMZ) 
components, and circulating autoreactive T cells against BMZ components have been 
demonstrated in LS patients.67-69
Patients with LS often present with severe pruritus and soreness of the vulvar 
and perianal area, but a few patients may be asymptomatic.59,60,70 Lesions are white 
with textural changes as atrophy or hyperkeratosis, and appear as a figure-of-eight 
pattern around the vulva and anus. In advanced stages, there is destruction of vulvar 
anatomy characterized by resorption of labia, narrowing of the introitus and a buried 
clitoris. Histologically, LS is characterized by a thinned epidermis, vacuolar changes in 
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the basal layer, a band of homogenized collagen below the dermoepidermal junction 
and a band-like lymphocytic infiltrate.59
Since no cure exists for LS, therapies are primarily directed to reduce symptoms. 
Topical treatment with ultrapotent corticosteroids has proven to be the most effective 
treatment option.71,72 In addition, as mentioned in section 1.3.2, LS can progress to 
dVIN and subsequent vulvar SCC, although the exact pathogenesis is still unknown. 
Reported rate of progression to invasion is 4-5%.59 Therefore, life-long follow-up is 
important. 
1.5 lIchen planus
LP is another inflammatory dermatosis, which may involve the skin and mucosal 
surfaces. Most frequently the oral cavity and vulvovaginal area are involved.73 
The prevalence of LP is unknown, it accounts for about 1% of new cases seen in 
dermatology departments, and vulvar LP is diagnosed in about 3-6% of all patients 
seen in vulvar clinics.73-75 Age of onset is generally between the fifth and sixth 
decade.73,76,77 Similarly to LS, the etiology of LP is uncertain. There is evidence that it is 
immunologically mediated, since an association with HLA DRB1*0201 and autoimmune 
diseases as thyroid disease and vitiligo has been reported.66,78 Autoreactive T cells and 
autoantibodies to BMZ components have also been demonstrated in LP.67,79 However, 
the precise mechanisms leading to LP are unknown. 
The clinical presentation of vulvar LP can be variable, and LP can affect the vulva 
in three different variants: a classical, a hypertrophic or an erosive form.73 Erosive 
LP is most common, and in contrast to LS, vaginal involvement has been reported 
in up to 84% of patients with erosive LP.73,75 Patients present with vulvar soreness, 
pruritus, burning, dyspareunia, and often vaginal discharge. Erosive lesions with 
denuded epithelium associated with typical white Wickham’s striae can arise in 
vulvar or vaginal mucosa, and alteration of normal vulvar architecture may occur. In 
severe cases, adhesions and stenosis can lead to complete obliteration of the vagina. 
Histologically, LP is characterized by irregular acanthosis of the epidermis, basal cell 
liquefaction, and a band-like lymphocytic dermal infiltrate.73,76,80 
As for LS, no curative therapy exists and topical treatment with ultrapotent 
corticosteroids is the first-line treatment option, although it does not abolish 
symptoms in the majority of patients.76,77 Vaginal dilatators can be helpful in case 
of obliteration, but in severe cases surgery is needed to restore sexual function. 
Although the malignant potential of LP is unknown, malignant transformation to 
vulvar SCC has been reported in a few studies.81,82 Therefore, likewise in patients with 
LS, life-long follow-up of LP patients is important.
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1 1.6 outlIne of thesIs
It is important that healthcare providers such as gynecologists and dermatologists are 
aware of the clinical features, behavior and management of different vulvar epithelial 
disorders, and therefore an extensive description about the relevant aspects of VIN, 
vulvar Paget’s disease and melanoma in situ is given in Chapter 2.
Although imiquimod has proven to be an effective treatment for uVIN, long-term 
follow-up data about recurrence rates are still lacking. For that reason, the aim of the 
study described in Chapter 3 was to evaluate long-term (>5 years) clinical response 
of VIN after imiquimod treatment.
Because previous observations demonstrated that success of imiquimod treatment 
in VIN patients is related to clearance of hrHPV, we assessed in Chapter 4 immune cell 
counts and expression of P16ink4a in VIN tissue before and after imiquimod treatment, 
in relation to HPV clearance and clinical response.
Local inflammation and burning are common side effects of imiquimod treatment 
and patients often use nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce these 
side effects. It is known that NSAID-use can potentially inhibit cell-mediated immune 
response, and therefore we investigated in Chapter 5 whether NSAID-use interferes 
with the outcome of imiquimod treatment.
Treatment of VAIN is a challenge, with considerable morbidity and high recurrence 
rates. As for VIN, the underlying cause of VAIN is a persistent hrHPV infection. 
Chapter 6 describes the results of a pilot study about the efficacy of imiquimod as a 
treatment for VAIN.
In Chapter 7, the immunological mechanisms involved in LS and LP were 
investigated in order to further clarify the pathogenesis of both diseases.
In Chapter 8, the main findings of this thesis are discussed and related to current 
and future perspectives about treatment of premalignant vulvar epithelial disorders.
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aBstract
no standard screening programs exist to detect vulvar carcinoma or its 
precursor lesions, and therefore gynecologists, dermatologists and other 
healthcare providers in this field should be aware of the clinical features, 
behavior and management of the different existing premalignant vulvar 
lesions, squamous vulvar intraepithelial neoplasia (vIn), vulvar paget’s disease 
and melanoma in situ. In 2004, a new classification for squamous vIn was 
introduced by the International society for the study of vulvovaginal disease 
(Issvd), subdividing squamous vIn into the hpv-related usual	 type, and 
into differentiated	 type, which is associated with lichen sclerosus. this review 
describes the relevant aspects of squamous vIn, vulvar paget’s disease and 
melanoma in situ, its epidemiological characteristics, diagnosis, management, 
and malignant potential. 
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vulvar IntraepIthelIal neoplasIa
terminology and classification
Squamous vulvar intraepithelial neoplasia (VIN) is a premalignant skin disorder that 
often causes severe and long-lasting pruritus, pain, and psychosexual dysfunction. It 
has a spectrum of clinical and histopathological appearances and can be divided into 
two subtypes: usual type VIN, which is caused by a persistent infection with high-risk 
human papillomavirus (HPV), and differentiated type VIN, which is associated with 
lichen sclerosus (LS). Squamous intraepithelial lesions were first described in 1912 
by Bowen, and since then various terms have been used. In 1965, Kaufman grouped 
premalignant lesions into three categories: Queyrat’s erythroplasia, Bowenoid 
carcinoma in situ, and carcinoma simplex.1 A new simplified terminology was 
introduced by the International Society for the Study of Vulvovaginal Disease (ISSVD) 
in 1976, and all terms were replaced by carcinoma in situ and vulvar atypia.2 Ten 
years later these terms were replaced by a single term, vulvar intraepithelial neoplasia 
(VIN).3 In addition, VIN was graded, similar to cervical intraepithelial neoplasia (CIN), 
in three subtypes, VIN 1 (mild dysplasia), VIN 2 (moderate dysplasia) and VIN 3 
(severe dysplasia).3 This grading system suggests a biologic continuum of VIN lesions. 
However the presence of such a continuum is not supported by clinicopathological 
data. Therefore, the ISSVD abolished the grading system in 2004 and introduced 
a 2-tier classification for squamous VIN: usual	type and differentiated	type VIN. The 
two types differ in etiology, morphology, biology, clinical features and malignant 
potential.4,5 However, the WHO-classification with the three subtypes VIN 1, 2 and 3 
is still widely used.6
Usual	 type	 VIN (uVIN) has histologically been divided into warty, basaloid or 
mixed (warty/basaloid) VIN. uVIN is caused by a persistent infection with high-risk or 
oncogenic HPV (mostly HPV-type 16, 18 or 33).7 It occurs predominantly in younger 
women and tends to be multifocal.4  
Differentiated	type VIN (dVIN) is less common, <2-5% of all VIN lesions are of 
this type, but it has the highest malignant potential.1,8 It is not related to HPV but 
associated with LS and is usually found in older women.9 dVIN is mostly unicentric and 
strongly associated with past or coincident invasive vulvar squamous cell carcinoma 
(SCC).10,11   
Besides modifying the classification of VIN, the ISSVD also modified the grading 
system. Some studies demonstrated an overlap in the diagnosis of VIN 2 and VIN 3, 
while it was shown that VIN 1 only occurred in condylomata acuminata.10,12 In addition, 
it was demonstrated that there is a lack of reproducibility of the pathologic diagnosis 
of VIN 1, 2 and 3, and that VIN 2 and 3 grouped together is better reproducible.12,13 
Nowadays, the term VIN is only applied to histologically ‘high-grade’ squamous 
lesions (VIN 2 and VIN 3). VIN 1 no longer exists. 
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epidemiology 
Over the last decades, the incidence of VIN has increased, most likely due to a rise in 
incidence of HPV infections. Overall incidence of vulvar SCC remained the same.8,14-16 
However, some studies reported an increase of vulvar SCC in younger women who 
tend to have a history of HPV and VIN.16-18 A recent study observed the incidence 
of uVIN, dVIN and vulvar SCC in the Netherlands during a 14-year-period. The 
incidence of uVIN almost doubled from 1.2/100,000 patients in 1992 to 2.1/100,000 
patients in 2005 and that of dVIN increased nine-fold from 0.013/100,000 patients 
to 0.121/100,000 patients, while the incidence of vulvar SCC remained stable.8 The 
incidence of invasive vulvar SCC increases with age8,19 and a higher rate of vulvar SCC 
has been observed in white women than in women of other races.19
etiology
Usual	type	vulvar	intraepithelial	neoplasia.	Lifetime risk to become infected with HPV 
in western societies is around 80% and approximately 40% of all sexually active, 
female adolescents are at least once infected with high-risk HPV (hrHPV).20 When 
hrHPV persists (in less than 10% of cases), premalignant disorders of the lower 
anogenital tract, such as uVIN, can develop.21-23
The majority of VIN (90%) is of the usual type and persistent infection with hrHPV 
plays an important role in the etiology of uVIN. Reported prevalence of HPV in VIN 
range from 72 to 100% and in most cases HPV16 is detected.7,24-29 
Immunosuppression  and smoking (which reduces local immunity) are important 
risk factors for VIN30-34 and it is known that immunosuppressed patients as HIV-
positive women have an increased risk to develop uVIN.31,35,36 Several immunological 
studies demonstrated that the host immune response is of critical importance 
in determining clearance or persistence of HPV-related VIN.37-41 uVIN lesions are 
characterized by an immunosuppressive state in the epidermis,40,41 while a reduced 
and insufficient immune response to the hrHPV infection occurs in the dermis of 
uVIN.38,39,41 Furthermore, spontaneous regression of VIN has been observed with high 
detectable HPV-specific blood T-cell responses, while patients with persistent disease 
had no detectable anti-HPV T-cell responses.37 
In the HPV-related pathways, a couple of molecular alterations occur due to 
infection and subsequent integration of hrHPV. HPV encodes for several viral proteins, 
of which the oncoproteins E6 and E7 are the most important. HPV E6 can interact with 
the tumor suppressor gene p53, leading to p53 dysfunction and consequently absence 
of cell cycle arrest.42 HPV E7 can inactivate the retinoblastoma tumor suppressor 
gene pRb, which results in overexpression of the cell cycle related biomarkers p16ink4a 
and p14arf, and hyperproliferation of infected cells.43,44 As a result, most uVIN lesions 
are positive for p16ink4a and p14arf, but p53 negative.44-48 An increased expression 
of p16ink4a in combination with low p53 expression was observed in young women 
compared to older women with vulvar SCC.49
These markers are not conclusive in distinguishing uVIN from dVIN. It was observed 
that p16ink4a expression is high in all uVIN-associated tumors, but also in 10 of 105 
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dVIN-associated tumors. Almost all dVIN-associated tumors were HPV negative and 
none had integration of HPV, this is in contrast to the uVIN-related tumors of which 
23 of 25 had integrated HPV.50 Recently, it was shown that in all dVIN lesions gain of 
chromosome 3q26 was present, while this was only the case in 50% of uVIN lesions. 
Detection of 3q26 imbalance could be of additional diagnostic value in the diagnosis 
of VIN lesions together with staining for p16ink4a and p53.51
Differentiated	 type	 vulvar	 intraepithelial	 neoplasia. In contrast to uVIN, the 
presence of HPV in dVIN is very rare and the exact cause of dVIN is still unclear.11,50,52,53 
It is assumed that dVIN is related to LS9 and several reports show a clear relationship 
between dVIN and LS in adjacent skin of vulvar SCC.54-58 However, it seems that VIN 
associated with LS without	coexisting vulvar SCC is more likely of the undifferentiated 
type.59 Squamous hyperplasia is also commonly seen in adjacent epidermis of dVIN 
patients, and might be a step in carcinogenesis.11,60 dVIN is often HPV-negative and 
p53 positive.11,45,61,62
clinical features and diagnosis 
The clinical presentation of VIN is diverse. Lesions can be red, white and pigmented, 
either flat or raised, erosions or ulcers may be present. Symptoms as pruritus or 
pain are observed in about 60% of patients.63,64 Since patients can be asymptomatic, 
accurate vulvar inspection during routine gynecologic examination is important. 
Clinical features that can help in making the correct diagnosis are color, thickness, 
surface and focality.1 To confirm the diagnosis, a biopsy of the most suspicious part 
of the lesion should be performed under local anesthesia.65
Commonest affected sites are labia majora and minora and the fourchette.32,63 
uVIN lesions are often multifocal.9,63,64 In addition, multicentric disease (lesions of 
cervix, vagina or anus) is common in uVIN patients and is age-related, as it decreases 
from 59% in women aged 20-34 to 10% in women over 50 years of age.9,29,32,66 
Therefore, a careful examination of the lower anogenital tract (vulva, perineum and 
perianal areas) which also includes the cervix and vagina, is mandatory.
The diagnosis of dVIN is a challenge. dVIN lesions are almost always observed in 
areas of LS or lichen planus (LP), only one case report describes dVIN as a solitary lesion 
in a patient without a history of LS or LP.67 Red lesions and areas with hyperkeratosis, 
ulceration or having a rough and irregular surface are suspicious for dVIN.9,11 Patients 
are often symptomatic with a long-lasting history of LS or LP-related symptoms of 
vulvar itching and/or burning.11 
Because of the highly malignant potential of dVIN, any suspicious area in 
patients affected by LS or LP should be biopsied or excised without delay to obtain a 
representative histopathological diagnosis. 
histology
Usual	 type	 vulvar	 intraepithelial	 neoplasia.	 Histopathologically, uVIN can be 
classified into different subtypes: warty and basaloid. Both can be easily recognized. 
Typically, the epidermis is thickened and is accompanied by a surface reaction of 
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hyperkeratosis and/or parakeratosis. There is loss of cell maturation with associated 
nuclear hyperchromasia, pleomorphism and numerous mitotic figures at all levels 
of the epidermis.9 The intraepithelial process may also involve the underlying 
skin appendages.68,69 The epidermis of warty VIN has wide and deep rete ridges, 
often reaching close to the surface, which gives a characteristic condylomatous 
appearance. There is striking cellular polymorphism and evidence for abnormal cell 
maturation. Koilocytosis, corps rounds, multinucleation, (abnormal) mitotic figures 
and acanthosis are common.9 Basaloid VIN is characterized by a thickened epithelium 
with a relatively flat and non-papillomatous surface. Large numbers of relative 
uniform undifferentiated cells with a basaloid appearance are seen in the epidermis. 
Mitotic figures are numerous, but koilocytic cells and corps rounds are less frequently 
seen than in warty VIN. Patterns of warty and basaloid VIN are often found in the 
same lesion, which is referred to as mixed VIN.9
Differentiated	type	VIN can be easily mistaken for a benign dermatosis because 
of the high degree of cellular differentiation and absence of widespread architectural 
disarray.5,9,11,62 Histological characteristics include a thickened epithelium with 
parakeratosis, elongated and anastomizing rete ridges, and enlarged abnormal 
keratinocytes with premature eosinophilic cytoplasmic differentiation.9,11 These 
abnormal keratinocytes are confined to the basal and parabasal layers and are a 
hallmark of dVIN.9 No studies have been performed to investigate the reproducibility 
of the histopathological diagnosis of dVIN. Staining with MIB1 (Ki-67), a marker that 
visualizes proliferating cells, can be helpful in distinguishing dVIN from normal vulvar 
epithelium. The basal layer of dVIN is positive for MIB1, while normal vulvar epithelium 
is characterized by an almost MIB1-negative basal layer.70 Another tool that might 
be helpful is staining for p53 protein. Alteration in the p53 tumor suppressor gene 
appears to be involved in the development of dVIN and overexpression of p53 has 
been demonstrated in dVIN.11
psychosexual impact
Since the incidence of VIN has increased dramatically – particularly in younger 
women16 – attention should be paid to the psychosexual consequences of VIN and 
vulvar excision. However, the number of studies concerning psychosexual impact of 
VIN and vulvar surgery is limited. In general, surgical treatment of vulvar lesions may 
lead to disfigurement, postoperative loss of quality of life (QoL) and impaired sexual 
function.71-73 In addition, sexual function is correlated to the extent of excision.73,74 
Therefore, treatments which preserve the anatomy of the vulva such as imiquimod or 
CO2-laser vaporization can be important to prevent psychosexual sequelae. However, 
large studies comparing the effect on QoL of various treatments for VIN are lacking. A 
recent study evaluated the prevalence of psychological morbidity in women with VIN. 
Moderate-to-severe anxiety was observed in 32% and moderate-to-severe depression 
in 18% of women.75 These psychological factors were strong determinants of QoL, 
while clinical variables such as duration of disease, presence of symptoms and number 
of treatments did not have a measurable impact on QoL.75 In conclusion, clinicians 
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should give attention to the psychological and sexual consequences of VIN treatments. 
Future studies should focus on predictive factors that impair sexual function and QoL 
after excision for VIN and investigate whether outcomes on QoL and sexual function 
are better following anatomy- and function-preserving treatments.
treatment modalities
Usual	 type	 vulvar	 intraepithelial	 neoplasia. For a long time, choice of therapy for 
uVIN has been dominated by the premalignant nature of the disease. In the past, 
extensive surgery such as vulvectomy has been performed to remove the disease. 
However, surgical margins are often positive, irrespective of the type of surgery, and 
high recurrence rates are common.64,76,77 In 1995, Kaufman addressed the importance 
of individualization of treatment. Treatment should be directed towards preservation 
of the normal anatomy and function of the vulva.78 Therefore, more limited surgery 
consisting of surgical removal of all visible lesions has been the surgical technique 
of choice since the last decades.78 Surgical treatment can be performed with 
different techniques. Cold knife surgery or CO2-laser vaporization have been used 
as a single technique or in combination. Laser vaporization can be an effective 
method in non-hair bearing areas. But because this technique destroys all tissue, it is 
recommended to take representative biopsies beforehand.1,76 In conclusion, surgical 
treatment is effective in removal of premalignant lesions, but recurrence rates are 
high and one has to be aware of the effect of surgical treatment on quality of life 
and sexual function.
The main advantages of medical treatment are preservation of vulvar anatomy 
and function. Topical treatment is attractive because it can be applied directly by 
the patient and is easily monitored for efficacy. However, medical treatment does 
not provide a specimen for histological evaluation with the risk that early invasion 
is overlooked. Hence, taking accurate biopsies is important before starting medical 
treatment.
Imiquimod 5% cream is a topical immune response modifier that acts by binding 
on Toll-like receptor (TLR) 7 on the cell surface of dendritic cells, thereby inducing 
secretion of proinflammatory cytokines. This results in a profound tumor-directed 
cellular immune response.79,80 The effectiveness of imiquimod has been assessed 
in several studies. A systematic review showed the results of 210 patients from 17 
studies (1 RCT, 10 case series and 6 case reports). Treatment duration ranged from 
3 to 32 weeks and follow-up from 1 week to over 30 months. Complete regression 
was observed in 26-100% of patients, 0-60% had partial regression and 0-37% 
experienced recurrence. Most common adverse events were local burning and 
soreness.81 Recurrence data of imiquimod treatment compared with data from a 
historical cohort of surgically treated patients showed that the recurrence rate after 16 
months follow-up was 20.5% for imiquimod treated patients and 53.5% for surgical 
treated patients.82 Two double-blinded RCTs comparing placebo and imiquimod 
were performed.83,84 In the first, 31 patients were treated with an escalating dose 
regimen during 16 weeks. Complete regression was observed in 81% and partial 
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regression in 10% of the imiquimod treated patients, while none of the patients 
treated with placebo showed a response. No progression to invasive disease was 
observed.83 In the second RCT, a reduction in lesion size was observed in 81% of 
cases (35% complete responders, 46% partial responders), in comparison with 0% 
in the placebo group (P<0.001). In addition, no HPV DNA could be detected anymore 
in 58% of imiquimod treated patients. Two patients treated with placebo and one 
patient treated with imiquimod progressed to invasion (<1 mm). Reduction of lesion 
size was correlated with partial normalization of the numbers of immunocompetent 
cells.84 It was shown that imiquimod increases the magnitude of the HPV16 specific 
CD8+ T-cell activity in VIN patients, but magnitude and specificity of the response 
had no correlation with the clinical response.85 Another study investigated the role 
of HPV16-specific interferon-γ (IFNγ) associated CD4+ T-cell immunity in the clinical 
effect of imiquimod treatment.86 No enhanced HPV16-specific CD4+ T-cell response 
was seen upon imiquimod treatment, but, interestingly, a preexisting HPV-specific 
type 1 T-cell response was associated with a more favorable clinical outcome upon 
imiquimod treatment.86 Imiquimod is now recommended as a first-line treatment for 
VIN. However, long term follow-up data after imiquimod treatment have not been 
reported so far, but are expected in the near future.
Topical photodynamic therapy (PDT) uses a tumor-localizing photo sensitizer, 
5-aminolevulinic acid (ALA), in combination with non-thermal light of an appropriate 
wavelength to generate oxygen-induced cell death. Its efficacy has been proved in 
nonmelanoma skin cancer.87 Several nonrandomized and uncontrolled studies were 
conducted to assess the efficacy in uVIN. Response rates vary from 0 to 71%.88-93 
Small unifocal lesions often respond to PDT, but multifocal, pigmented and high 
grade lesions are less likely to respond.89,90 Furthermore, uVIN lesions that failed 
to respond were more likely to have detectable HPV levels than responsive uVIN 
lesions.88,90 Recurrence rate (around 48%) does not significantly differ from surgery 
or laser vaporization.94 Advantages of PDT are minimal tissue destruction, short 
healing time and limited side effects.88-93 Recently, a study was published in which 
20 uVIN patients were treated with sequential imiquimod combined with PDT. In this 
study, the overall response rate was 55% and at 52 weeks, 65% of patients were 
asymptomatic, compared to 5% at baseline.95
Therapeutic vaccines have been developed to enhance T-cell mediated immunity 
in uVIN lesions. Most vaccines elicit a specific immunity against the HPV E6 and E7 
proteins. A reduction in lesion size of at least 50% was observed in 8 of 18 women 
vaccinated with TA-HPV, a recombinant vaccinia virus,96 while others observed with 
the same vaccine a 50% reduction in lesion size in 5 of 12 patients. One patient 
showed complete regression.97 Two studies investigated the effectiveness of three 
immunizations with HPVL2E6E7 protein combined with a single dose of vaccinia HPV 
16/18 E6/E7 either before or after the immunizations.98,99 Of 39 patients, nine showed 
reduction in lesion size, while 25 remained stable and five patients progressed. It 
was shown that this regimen is immunogenic, but no relation between induction of 
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HPV-16-specific immunity and clinical outcome was observed.98,99 In a recent study, 
20 women with HPV-16-positive high-grade VIN were vaccinated 3 or 4 times with a 
mix of long peptides from the HPV-16 viral oncoproteins E6 and E7. At 3 months after 
vaccination, five had a complete regression of the lesions and this number increased 
to nine at 12 months after last vaccination. Complete response rate was maintained 
at 24 months of follow-up. In addition, a partial response was seen in seven patients 
after 3 months and in six patients at follow-up after 12 months. Vaccine-induced 
T-cell responses were seen in all patients. Complete responders had a significantly 
stronger response of IFNγ-associated proliferative CD4+ T cells and a broad response 
of CD8+ IFNγ T cells than did non-responders, and therefore, complete responses 
appeared to be correlated with induction of HPV-16-specific immunity.100
In the past, several other medical therapies such as 5-fluorouracil,	 cidofovir, 
interferons and indole-3-carbinol have been investigated as a treatment for VIN.101-105 
However, studies are small and due to limited effectiveness or severe side effects, 
none is considered as a standard therapy for VIN.
As indicated by the number of treatment options for VIN, none is 100% effective 
and a lot of treatments are a burden for the patient. Consequently, some patients 
may not want to undergo treatment. A wait-and-see policy, aimed at controlling 
symptoms and prevention of malignancy, is an option.106 Frequent follow-up visits are 
advised including careful examination and biopsies in case of suspected malignancy.
Since the host immune response plays an important role in clearance of HPV, 
prophylactic vaccination could be effective in prevention of HPV-related disease. In order 
to prevent infection and subsequent development of CIN and cervical cancer, several 
vaccines have been developed during recent years. There is a quadrivalent vaccine, 
which acts against HPV 16, 18, 6 and 11 and a bivalent vaccine, which acts against 
HPV 16 and 18. In a combined analysis of three randomized trials, vaccination with the 
quadrivalent vaccine was 97% effective in preventing uVIN associated with HPV 16 and 
18 in a population that was naive to these viruses at time of first vaccination and 100% 
effective in a population that was naive throughout completion of the vaccination 
regimen. In the intention-to-treat population (which included women who, at day 1, 
could have been infected with HPV 16 or HPV 18), vaccine efficacy was 71%.107 There 
are no data on the prevention of uVIN by the bivalent vaccine.
Differentiated	 type	 vulvar	 intraepithelial	 neoplasia. The preferred treatment for 
dVIN is radical surgical excision, as it occurs often in correlation with invasive SCC. 
Follow-up should take place at a specialized vulvar clinic or by a vulvar specialist who 
has had additional training in managing vulvar disease.108
malignant potential
Usual	 type	 vulvar	 intraepithelial	 neoplasia. Although dVIN has a much higher 
malignant potential than uVIN,8,11,57,67 the malignant potential of uVIN should not be 
underestimated. It has been shown that uVIN is highly proliferative.109 A meta-analysis 
showed that 8/88 (9%) of untreated uVIN patients developed invasive SCC within 
1-8 years.64 Others observed a much higher percentage, 10/63 (15.8%) of untreated 
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patients progressed in 1.1-7.3 years.76 In treated patients, rate of progression during 
follow-up after treatment was 3.3% (208/3322).64 Progression rate was not affected 
by the surgical extent.64 A population-based study from Norway showed that free 
resection margins did not prevent progression to invasive SCC. In this study, 50% 
of patients who developed vulvar SCC after treatment had free surgical margins.15 
Therefore, one should not enlarge the extent of resection to prevent progression. 
The malignant potential of uVIN is also illustrated by the finding of occult 
carcinomas in VIN. A recent study showed an occult cancer rate in vulvar biopsies 
of 3.8% for VIN 2 and 11.9% for VIN 3 (the term uVIN was not used).110 Other 
studies reported occult carcinoma rates of 3.2-18.8%.64,111 Known risk factors for 
progression of uVIN are advanced age, raised lesions, immunosuppression and 
radiotherapy.8,64,112 In addition, it has been suggested that basaloid type uVIN is of 
greater risk to progress than warty type.5
Spontaneous regression has also been described in patients with uVIN. It was 
observed in 1.2% of patients, all were younger than 35 years and often related to 
pregnancy,64 presenting most often with multifocal pigmented lesions.76
Differentiated	 type	vulvar	 intraepithelial	neoplasia.	A recent study showed that 
the overall percentage of dVIN lesions with subsequent diagnosis of SCC was 32.8% 
while this was 5.7% for uVIN lesions. Furthermore, median time from dVIN to SCC 
was 22.8 months, while median time from uVIN towards SCC was 41.4 months.8 The 
relation between a prior, synchronous or subsequent vulvar carcinoma and dVIN is 
three times higher than uVIN (85.7% vs. 25.7%).57 Furthermore, vulvar cancer arising 
on a background of dVIN appeared more likely to recur than cancers arising from 
uVIN.58 Another study also noted that the prognosis in terms of 5-year disease-free 
and overall survival rate were worse in patients with vulvar SCC associated with LS 
and squamous cell hyperplasia ‘with or without atypia’ (the term dVIN was not used) 
than in patients with uVIN-associated SCC.113 
conclusion
The incidence of VIN has increased. It is of critical importance to distinguish uVIN 
from dVIN. Both subtypes have a different clinical appearance, pathology and – most 
important – malignant potential. Radical surgical excision is treatment of choice for 
dVIN, while a more conservative approach is recommended for uVIN lesions. uVIN 
occurs predominantly in younger women and an individual approach, including 
attention for the psychosexual sequelae, is important. Because of high recurrence 
rates after various treatments, a thorough follow-up regimen by trained vulvar 
specialists is recommended.
Recently, most western countries introduced prophylactic vaccination against 
HPV, which can potentially prevent most HPV-related premalignant lesions and about 
one third of all vulvar carcinomas. In the mean time, further studies are needed to 
improve treatment outcome.
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vulvar paget’s dIsease
In 1986 the ISSVD classified vulvar extramammary Paget’s disease (EMPD) as a 
non-squamous intraepithelial lesion of the vulva.3 Vulvar EMPD is a relatively rare 
intraepithelial carcinoma. It affects mainly postmenopausal women, with a median 
age of 72 years. The most common signs and symptoms are itching, burning, 
moistening and bleeding, for up to 5 years.114-118 Substantial delay between 
appearance of symptoms and diagnosis can occur in many patients, and this is 
significantly associated with larger lesions.119 It is usually multifocal and may occur 
anywhere on the vulva, mons, perineum, perianal area, or inner thigh. There are 
often multiple extensive lesions presenting as moderately well demarcated, scale, 
moist, eczematoid, erythematous-white plaques often dotted with small, pale islands. 
Vulvar EMPD predominantly is an intraepithelial lesion, but has the potential 
for dermal invasion and on occasion has been associated with an underlying 
adenocarcinoma. In one large study, 26% of patients had other primary tumors, 
such as breast, pancreas, endometrium, bladder, stomach and rectum malignancies. 
Associated vulvar adenocarcinoma (4%) and invasive vulvar EMPD (16%) may 
frequently coexists and recurrence rate of vulvar EMPD is high (35%).114 Like in 
squamous cell carcinoma of the vulva, there is evidence to support the recognition of 
a category of minimally invasive vulvar EMPD (≤1 mm depth of invasion), that has a 
low risk of distant metastasis and death caused by disease.120,121 
Histopathological examination shows epidermal acanthosis and elongated 
rete ridges. Paget’s cells are large intraepidermal cells with a large nucleus that 
often has a prominent nucleolus and abundant usually clear, mucin positive, pale 
cytoplasm. The cells may occur singly in small clusters or large nests. The squamous 
epithelium is often hyperplastic with hyper- or parakeratosis. The Paget’s cells may 
extend into the adnexal duct and pilosebaceous units114,118,121 and they may be a 
proliferation of adnexal stem cells residing in the infundibulo-sebaceous unit of hair 
follicles and adnexal structures.122 It has been suggested that at least a proportion 
of vulvar EMPD arises multicentrically within the epidermis from pluripotent stem 
cells.123 There is evidence that vulvar EMPD represents a heterogeneous group of 
epithelial neoplasms that can be similar both clinically and histopathologically. Vulvar 
EMPD can be classified based on the origin of the neoplastic Paget’s cells as either 
primary (of cutaneous origin) arising within the epithelium of the vulva, or secondary 
(of noncutaneous origin), resulting from the spread of an internal malignancy, 
most commonly from an anorectal adenocarcinoma or urothelial carcinoma of the 
bladder or urethra, to the vulvar epithelium. Primary EMPD can be further subdivided 
into a primary, intraepithelial cutaneous form with and without invasion and into 
an intraepithelial cutaneous Paget’s disease as a manifestation of underlying skin 
appendage adenocarcinoma. Secondary EMPD has an anorectal, urothelial or other 
origin. These subtypes can present similarly on the skin and may appear similar on 
routine hematoxylin and eosin-stained slides. Immunohistochemical studies can be 
used to help differentiate them. Primary vulvar EMPD is immunoreactive for CK 7 
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and GCDFP-15, but uncommonly for CK 20. Vulvar EMPD secondary to anorectal 
carcinoma demonstrates CK 20 immunoreactivity but is usually nonreactive for CK 
7 and consistently nonimmunoreactive for GCDFP-15. Vulvar EMPD secondary to 
urothelial carcinoma is immunoreactive for CK 7 and CK 20 but nonimmunoreactive 
for GCDFP-15. In addition, UP-III, which is specific for urothelium, is immunoreactive 
in secondary vulvar EMPD of urothelial origin. The distinction is important in that the 
specific diagnosis has a significant influence on current treatment.124,125 
Wide local excision is the usual treatment of EMPD to a dept of 4-6 mm to include 
the pilosebaceous units and skin adnexal structures. Patients with an underlying 
adnexal adenocarcinoma or stromal invasion of EMPD over 1 mm should be treated 
more aggressively, with excision to the fascia in the involved area, and inguinofemoral 
lymphadenectomies bilaterally. Vulvoperineal reconstruction may be necessary by 
means of skin grafts, local skin flaps, muscle flaps and different fasciocutaneous 
flaps.126 Based on small series, topical 5% imiquimod cream has been shown as a safe 
treatment and may induce complete responses in primary or recurrent vulvar EMPD. 
The therapeutic schedule used varies. A daily application for 3 weeks, followed by 
an every other day application for an additional 3 weeks seems to be effective.127-129 
The role of photodynamic therapy130,131 in the multimodal approach to extensive or 
recurring vulvar EMPD is still unclear. Radiation therapy in selected cases may be 
feasible and effective.132 Overexpression of the HER-2/neu protein has been found 
in about 30% of vulvar EMPD cases. Targeted therapy with trastuzumab may be 
considered as a possible new therapeutic strategy in selected cases of vulvar EMPD 
showing overexpression of HER-2/neu. Treatment can result in a significant regression 
of disease and resolution of symptoms.133 Vulvar EMPD with Her-2/neu expression 
shows higher recurrence rates suggesting a more aggressive behavior.134 
Recurrences are common114,135 and may relate to the fact that the extent of 
histologically demonstrable disease is far greater than that of the visible lesion, 
the outline of the involved area is highly irregular and multiple foci of disease are 
present.136 There is no correlation between disease recurrence and margin status, thus 
disease recurrence is common, regardless of surgical margin status.118,132,137 Disease 
involving the perineum is suggested to be a significant risk factor for recurrences. 
Intra-operative frozen section analysis of the margins as well as radical surgery as 
initial treatment seems not to reduce recurrence rate.132 Long-term monitoring is 
recommended, as recurrences are common and can be noted many years after the 
initial treatment and repeat surgical excision is often necessary.
melanoma In sItu of the vulva
Melanoma in situ (MIS) is rare on the vulva and appears to have a relatively slow but 
definite progression to invasive melanoma.138 The ABCDE scheme for recognition 
of melanoma should be considered in pigmented lesions (Asymmetry, Border 
irregularities, Color variation, diameter >6 mm, enlargement or evolution of color 
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change, shape or symptoms).139,140 All suspicious pigmented lesions in this region 
should be biopsied and a punch biopsy is the preferred method because establishing 
the depth of such lesions is critical. Destruction by cryosurgery, cautery or laser is 
contraindicated, and all such lesions must undergo histopathological evaluation. 
Small lesions often can be completely excised, and when sampling hyperpigmented 
areas, a biopsy of the thickest region is recommended.138,141 If the diagnosis is 
considered within the differential diagnosis of pigmented vulvar lesions, it is easy to 
recognize and treat, with excellent prognosis.142 An excisional biopsy of the entire 
clinically apparent lesion, with a narrow 1- to 2-mm margin of adjacent normal-
appearing skin, is the biopsy technique of choice when melanoma is suspected, and 
shave biopsies should be avoided. An incisional biopsy may be acceptable for larger 
lesions, since studies have shown no worse prognosis if the initial biopsy does not 
remove the entire lesion, which is later excised.143,144 In MIS the proliferating malignant 
melanocytes are confined to the epidermis. Although an in-situ phase exists for three 
of the four invasive forms of melanoma, superficial spreading melanoma, lentigo 
maligna melanoma, and acral lentiginous melanoma, for the clinician it is irrelevant, 
since it should be removed anyway. For patients with MIS, there are no data from 
randomized trials to define the optimal extent of surgical resection. However, 
retrospective data support the routine use of 0.5 cm margins.145,146
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aBstract
Objective. recently we reported on the efficacy of imiquimod for treating 
vulvar intraepithelial neoplasia (vIn) in a placebo-controlled, double-blinded 
randomized clinical trial (rct). four weeks after treatment, a complete 
response was observed in 35% of patients and a partial response in 46%. all 
complete responders remained disease-free at 12 months follow-up. In the 
current investigations, we assessed long-term follow-up at least 5 years after 
the initial rct. 
Methods. twenty-four of 26 imiquimod-treated patients who had 
participated in the initial rct were seen for follow-up. primary endpoint 
was durability of clinical response to imiquimod assessed by naked eye vulvar 
examination and histology. long-term clinical response was correlated to 
lesion size before start of the initial rct. secondary endpoints were mental 
health, global quality of life, body image and sexual function in relation with 
long-term clinical response. 
Results. median follow-up period was 7.2 years (range 5.6-8.3 years). vIn 
recurred in one of nine complete responders. of the initial partial responders, 
two became disease-free after additional imiquimod treatment. In the other 
partial responders, vIn recurred at least once after the initial rct. In long-term 
complete responders, lesion size at study entry was smaller and these patients 
had a significantly better global quality of life at follow-up than patients with 
residual disease and/or recurrence after imiquimod treatment.
Conclusions. In case of a complete response, imiquimod is effective in 
the long-term. furthermore, patients with a long-term complete response 
had a significantly better global quality of life than patients who recurred 
after imiquimod treatment.
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IntroductIon
Vulvar intraepithelial neoplasia (VIN) is a premalignant skin condition that often 
causes severe and long-lasting pruritus, pain and psychosexual dysfunction.1 It can 
be classified into differentiated	type VIN, which is associated with lichen sclerosus, 
and usual	 type VIN,2 which is caused by a persistent infection of high-risk human 
papillomavirus (hrHPV).3 Usual type VIN tends to be multifocal, and occurs mainly in 
younger women.2 Furthermore, it has a certain invasive potential: 9% of untreated 
patients will progress to invasive vulvar cancer within 1-8 years and 3.3% will 
progress after treatment.4 
For a long time, surgical removal of all visible lesions was the standard treatment 
for VIN.5 However, surgical treatment often leads to disfigurement, postoperative 
loss of quality of life and impaired sexual function.6-8 In addition, recurrences are 
common after surgery, since the underlying cause  – a persistent hrHPV-infection  – is 
not cleared.4,9 
The immune response modifier imiquimod was recently introduced as an alternative 
for surgery. In a placebo-controlled, double-blinded randomized clinical trial (RCT), 
a complete response was observed in 35% of patients and a partial response in 
46%, and all complete responders remained disease-free at 12 months follow-up.10 
Moreover, when the histologic diagnoses were defined in accordance with the latest 
International Society for the Study of Vulvovaginal Disease (ISSVD) VIN terminology2 
in which only VIN is used instead of VIN 1-3, histologic regression was complete 
in 58% of patients. Another RCT, with a follow-up period of 12 months, reported 
a complete response after imiquimod treatment in 81% of patients.11 However, data 
on long-term follow-up after imiquimod treatment are still lacking. Published studies 
all suffer from small numbers or relatively short follow-up periods with median 
follow-up periods ranging from 5.5 to 30.5 months.10,12 Therefore, in the current 
study we have evaluated durability of clinical response to imiquimod at least 5 years 
after the initial RCT10 in which VIN patients were treated with imiquimod. 
patIents and methods
patients and study design
All imiquimod-treated patients who had participated in our initial placebo-controlled, 
double-blinded RCT10 were invited for an additional follow-up assessment. During this 
follow-up visit, we used the same standard questionnaire as used in the initial RCT to 
review changes in medication or smoking habits and asked whether any treatment for 
VIN or other premalignant and malignant lesions in the anogenital tract had occurred 
since the last follow-up visit at 12 months. All these self reported data as well as 
detailed clinical and pathological data obtained from the medical files were evaluated.
To evaluate long-term response, a vulvar naked eye examination was performed 
during the follow-up visit. When vulvar lesions suspicious for VIN or malignancy were 
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noted, photographs were taken of the lesions as described earlier.10 If no lesions 
were visible, photographs were taken of the site of the original lesions treated during 
the initial RCT. Photographs taken at the current follow-up visit were compared with 
those taken during the initial RCT.
If a recurrence was suspected in those patients who had a complete response 
in the initial RCT, a 4-mm punch biopsy was obtained. Biopsy specimens were 
used for histologic analysis according to the ISSVD VIN terminology2 (reviewed by 
an experienced gynecologic pathologist (P.C.E)) and for HPV DNA testing. To compare 
the presence of HPV in biopsies taken at follow-up with biopsies taken earlier, 
the SPF10-LiPA system (SPF10 HPV LiPA version 1, Labo Biomedical Products, Rijswijk, 
the Netherlands) was also performed on biopsy samples taken from these patients 
during the initial RCT.13 Furthermore, long-term clinical response was correlated with 
lesion size before start of the initial RCT, measured as described earlier.10 
Mental health was assessed with the use of the Medical Outcomes Study 36-Item 
Short-form General Health Survey and health related quality of life was assessed with 
the European Organization for Research and Treatment of Cancer (EORTC) quality-
of-life questionnaire (QLQ-30).14-16 Body image and sexuality were assessed with the 
QLQ-BR23.17 These questionnaires had also been used during the initial RCT.
Primary endpoint was durability of clinical response to imiquimod assessed by 
naked eye vulvar examination and, in case a recurrence was suspected in patients with 
an initial complete response, by histologic examination. Secondary endpoints were 
mental health, global quality of life, body image and sexual function in long-term 
complete responders and in patients with residual disease and/or recurrence after 
imiquimod treatment. 
All women provided written informed consent for this additional follow-up 
assessment and the study was conducted in accordance with the Declaration of 
Helsinki and Good Clinical Practice guidelines. 
statistical analysis
Data analysis was performed with the use of the SPSS 15.0 software package for 
Windows. 
Patients were divided in two groups for analyses: patients with a long-term 
complete response and patients with residual disease and/or recurrence after the 
initial RCT. Data distribution of variables (lesion size, mental health, global quality 
of life, body image and sexual function) was assessed with the Kolmogorov-Smirnov 
test. Distribution was normal for all of these variables. Since both groups were similar 
for baseline characteristics (age, follow-up period, smoking status, and other HPV 
lesions, tested with the Mann-Whitney test), differences in mental health, global 
quality of life, body image and sexuality were measured with one-way analysis of 
variance. Differences in lesion size before study entry were measured with the Welch’s 
corrected unpaired t-test. A two-tailed P-value of P<0.05 was chosen to represent 
statistical significance. 
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results
patients
Twenty-four of the original 26 imiquimod-treated patients responded and came to 
our outpatient clinic for an additional follow-up assessment. Two patients were lost 
to follow-up assessment; for these patients data were retrieved from medical files. 
One of them had an initial reduction in lesion size of 26-75% and was treated 
twice with laser vaporization after the initial RCT. Recurrence of VIN after the second 
laser treatment was treated with vaccination by application of long peptides from 
the HPV 16 viral oncoproteins E6 and E7 in another hospital.18 She had a partial 
response to vaccination, and therefore was treated with laser vaporization afterwards. 
The other patient lost to follow-up had an initial partial response of 76-99% and 
was treated elsewhere for basaloid anal carcinoma, stage T2N0. After treatment with 
radiotherapy, she had two recurrences of VIN without invasion and was treated with 
local excision. Of the 24 patients who were seen for follow-up, nine had a complete 
response to imiquimod in the initial RCT, four had a partial response of 76-99%, 
six had a partial response of 26-75%, and five patients had no response (Table 1). 
Median age of our study population at time of current follow-up was 48 years (range, 
29 -64 years). Median time between the current follow-up visit and start of the initial 
RCT was 7.2 years (range, 5.6-8.3 years). 
durability of clinical response in patients initially assessed as 
complete responders
Median follow-up period for the complete responders was 7.3 years (range, 5.6-8.3 
years). Eight of nine complete responders had not received any treatment for VIN 
between the initial RCT and the current follow-up visit and were still disease-free 
(Table 1, Figs. 1 and 2). In one of the complete responders a recurrence of VIN was 
diagnosed 4 years after the initial RCT at the same location as the original lesion 
treated during the RCT, and she was treated with laser vaporization (Table 1, patient 
11). At time of follow-up visit, she again had a lesion suspect for VIN at the same 
location and a biopsy was taken. Histologic diagnosis was VIN, and HPV 16 was 
detected. A vulvar biopsy was also taken in three other complete responders to rule 
out VIN. Histologically, no VIN was diagnosed in these three biopsies, and in two of 
three biopsies no HPV was detected (Table 1, patients 6 and 7). The third patient 
presented with condylomata acuminata, which was histologically confirmed, and an 
infection with HPV 6 and HPV 16 was detected (Table 1, patient 8).  
follow-up in patients initially assessed as partial or non-responders
Median time to follow-up of the initial partial and non-responders was 7.2 years (range, 
5.7-8.3 years). All but two partial responders were treated for their residual lesions 
by local excision or laser vaporization. One patient with an initial partial response 
of 76-99% had two residual lesions which regressed after an additional imiquimod 
treatment for 12 weeks. At time of follow-up visit, she was still free of disease 
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(Table 1, patient 9 and Fig. 1). Another patient with an initial partial response of 
26-75% had a residual lesion on the clitoris after treatment in the RCT, and imiquimod 
was applied once a week for an additional period of 2 months. She became a complete 
responder after treatment and is still disease-free (Table 1, patient 10, and Fig. 1). 
All other patients had additional treatments for their residual disease and had 
one to six treatments for recurrence of VIN between the initial RCT and the current 
follow-up visit (Table 1 and Fig. 1). Most patients were treated with local excision 
or laser vaporization. Five of them also received one or more imiquimod treatments 
during follow-up (Table 1, patients 14, 16, 17, 22 and 24). Of the patients with 
additional imiquimod treatments, one patient had a VIN lesion next to the urethra 
which did not respond during the initial RCT. After the RCT, she was treated with 
laser vaporization but had a recurrence after 1 year. Thereafter she was treated 
with a periurethral skinning local excision followed by pudendal transposition to 
restore the defect. One year later she suffered once more from a recurrence. She 
was again treated with imiquimod, but now she was instructed to apply the cream 
after thoroughly drying off the lesion. This resulted in a complete response (Table 1, 
patient 24). Of the other four patients who had additional imiquimod treatments, 
Figure 1. Clinical response at 20 weeks, 12 months and >5 years after start of imiquimod treatment. 
1Clinical response at 20 weeks and 12 months was classified as no response (reduction in lesion size 
of 25% or less), weak partial response (PR, 26-75% reduction), strong partial response (76-99% 
reduction), or complete response (CR, 100% reduction). 2One patient with a weak partial response 
was lost to follow-up at 12 months because of unrelated medical problems, but this patient did show 
up for long-term follow-up. Another patient with a weak partial response progressed to invasion (<1 
mm) at 7 months. She underwent surgery before follow-up at 12 months, so total lesion size was 
not measured at 12 months. 3One patient developed squamous cell carcinoma at 24 months and was 
treated with local vulvar excision and lymphadenectomy. 4One patient developed microinvasive squa-
mous cell carcinoma at 38 months and was treated with local vulvar excision.
Response at 12 months 
Imiquimod 
n=26 
No data 
n=22 
Response at >5 years  
Total: n=16 
  
Response1 at 20 weeks 
No response 
n=5 
Weak PR 
n=7 
Strong PR 
n=5 
CR 
n=9 
No response 
n=5 
Weak PR 
n=6 
Strong PR 
n=4 
CR 
n=9 
CR 
n=8 
CR 
n=1 
CR 
n=1 
CR 
n=0 
Recurrence 
n=1 
Residual disease/  
recurrence 
n=33 
Residual disease/ 
recurrence 
n=54 
Total: n=10 
Residual disease/  
recurrence 
n=7 
Figure 1 
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one patient with no response during the initial RCT showed a complete response 
after 2 months of imiquimod treatment but had again a recurrence 5 months later 
(Table 1, patient 22). 
The lesion sizes of long-term complete imiquimod-responders (Table 1, patients 
1–10) were significantly smaller than those of patients with residual disease and/or 
recurrence (Table 1, patients 11–26) (2.6±2.1 cm2 vs. 9.0±6.7 cm2, P=0.002). 
progression to invasion
One patient with a partial response of 26-75% progressed to invasion at 7 months 
as described previously.10 Depth of invasion was <1 mm, and a radical excision was 
performed. She had five recurrences of VIN afterwards that did not progress to 
invasion (Table 1, patient 16).
One patient with no response during the initial RCT had a local excision for the 
residual lesions after the RCT, and had a recurrence of VIN 34 months after start of 
T=0 T=20w 
T=0 T=20w T=67 months 
T=73 months 
T=0 T=20w T=87 months 
Patient 1 
Patient 2 
Patient 3 
Figure 2 
Figure 2. Clinical results before imiquimod treatment, 4 weeks after treatment and at >5 years fol-
low-up. Clinical pictures of three patients with HPV DNA-positive VIN showing results before treat-
ment (T=0), 4 weeks after treatment (T=20 weeks) and >5 years after treatment. All three patients 
showed complete regression of the lesion.
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the initial RCT. Four months later (38 months after start of the initial RCT), she again 
had perianal lesions and a biopsy was taken. She was diagnosed with squamous cell 
carcinoma (SCC) with an invasion depth of <1 mm. Additional excision of the lesion 
was performed and histologic evaluation showed VIN, without invasion. Afterwards 
she had a recurrence of VIN, for which she was treated with local excision. However, 
at time of long-term follow-up visit she again presented with a recurrence (Table 1, 
patient 23).  
Another patient with a partial response of 76-99% was diagnosed with SCC 
located on the left labium majus with an invasion depth of 0.5 cm, 2 years after start 
of the initial RCT. Wide local vulvar excision of the tumor with lymphadenectomy 
was performed, one gland was positive without extracapsular growth. She is now 
4 years post-treatment and has had no recurrence of the tumor, she did however have 
a recurrence of VIN, for which she was treated twice with imiquimod. She did not 
respond to the first treatment and underwent a second treatment with imiquimod at 
time of long-term follow-up visit. However, during this visit perianal and periclitoral 
VIN was diagnosed, and confirmed histologically (Table 1, patient 14).
other hrhpv-related lesions of the anogenital tract
None of the complete responders has been diagnosed with cervical intraepithelial 
neoplasia (CIN) or other hrHPV-related lesions after completing the initial RCT. Six 
partial responders had abnormal smear results between the initial RCT and the current 
follow-up visit. Two of these had CIN 1, the other four patients had no CIN lesion.
self-reported mental health, global quality of life, body image and 
sexual function
Patients with long-term complete response after imiquimod treatment (Table 1, 
patients 1–10) reported a significantly better global quality of life than patients with 
residual disease and/or recurrence (Table 1, patients 11– 4, P=0.025, Fig. 3). No 
statistically significant differences were observed between groups in scores on mental 
health, body image or sexuality.
dIscussIon
To our knowledge, this is the first study reporting on long-term clinical response of 
VIN after imiquimod treatment.12 In this study, eight of nine complete responders 
(89%) were still disease-free with a median follow-up of 7.3 years (range, 5.6-8.3 
years). In addition, two patients with a partial response became complete responders 
during follow-up after a prolonged treatment with imiquimod. In contrast, all other 
partial responders had one or more recurrences after imiquimod treatment. 
Several studies have indicated that imiquimod is an effective treatment for VIN. 
However, since these studies had short follow-up periods, it is unknown if imiquimod 
is a safe and effective treatment in the long term. Previous reported recurrence 
rates range from 0 to 37%, with median follow-up periods ranging from 5.5 to 
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30.5 months.12 The strength of the current study is the long follow-up period, with 
a median follow-up time of 7.2 years (range, 5.6-8.3 years). Although we were able 
to retrieve long-term follow-up data of all imiquimod-treated patients in the initial 
RCT, a limitation of this study is the relatively small sample size. Data on recurrences 
after complete response are based on a small population, since we had only nine 
initial complete responders and two complete responders after prolonged imiquimod 
treatment.  
Our long-term follow-up data demonstrate that 9% (1/11) of complete imiquimod 
responders developed a recurrence. This recurrence rate is lower than that observed 
for other treatments for VIN. Reported recurrence rates after surgical treatment are: 
0–19% after vulvectomy,4,19 15–17% after local excision with free surgical margins, 
and 46–50% after local excision with involved surgical margins.4,9,19,20 After laser 
vaporization there is a recurrence in 23–40% of patients,4,19 for photodynamic 
therapy (PDT) this figure is 48%.19 
A possible explanation for the low recurrence rate after imiquimod treatment could 
be that – in contrast with surgical treatments – there is clearance of hrHPV in complete 
responders, as we demonstrated previously.10 Since HPV infection is the underlying 
cause of the disease, VIN is less likely to recur in the patients that clear HPV. 
Although the GP5+/6+ PCR enzyme immunoassay21 was used during the initial 
RCT to detect HPV DNA in biopsies taken at 0 weeks and at 20 weeks, we decided to 
use the SPF10-LiPA system, because this is a more sensitive HPV test.
13 We also tested 
the biopsies taken before start of the initial RCT and at 20 weeks from patients who 
were biopsied at long-term follow-up with the SPF10-LiPA system. One patient who 
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Figure 3
Figure 3. Mental health, global quality of life, body image and sexual functioning. Scores (ranging 
from 0 to 100, mean ± SD) on mental health, global quality of life, body image and sexual functioning 
in patients with (Table 1, patients 1 – 10) and without (Table 1, patients 11 – 24) long-term complete 
response after imiquimod treatment. 1Patients with long-term complete response had a higher score 
on global quality of life (QoL) than patients with residual disease and/or recurrence (86±14 vs. 70±17, 
P=0.025, one-way analysis of variance).
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was tested HPV negative with the GP5+/6+ PCR enzyme immunoassay before start 
of the initial RCT, was tested HPV 33 positive with the SPF10-LiPA system, all other 
results were similar to the GP5+/6+ PCR enzyme immunoassay. At long-term follow-
up, hrHPV was detected in the complete responder with a recurrence (patient 11) 
and in the complete responder with perianal condylomata acuminata (patient 8), 
the same type (HPV 16) was detected as before start of the initial RCT. Since these 
patients had cleared HPV from the biopsied lesions at 20 weeks, it is likely that they 
were re-infected with hrHPV.
HPV exclusively infects epithelial keratinocytes and the virus does not elicit cell 
death, therefore infection is not accompanied by inflammation, which normally 
can activate the immune system. Consequently, it is difficult for the host immune 
system to recognize the virus during early stages of infection, which increases the 
risk for a persistent infection.22,23 Imiquimod modulates the immune response by 
binding on Toll-like receptors 7 and 8 on the cell surface of dendritic cells, thereby 
inducing secretion of proinflammatory cytokines.24,25 In this way, imiquimod alters 
the local immune response in favor of clearance of a persistent HPV infection. This 
therapeutic strategy is also used in vaccination trials.18,26 Kenter recently reported 
on 20 women with HPV-16-positive VIN that were vaccinated three or four times 
with a mix of long peptides from the HPV 16 viral oncoproteins E6 and E7.18 Three 
months after vaccination, 5 of 20 patients had a complete response, increasing to 
9 of 19 at 12 months after last vaccination (47%). Complete response rate was 
maintained at 24 months of follow-up. Complete responders had a significantly 
stronger response of IFNγ-associated proliferative CD4+ T cells and a broad response 
of CD8+ IFNγ T cells than did non-responders. Therefore, complete response appeared 
to be correlated with induction of HPV-16-specific immunity. Furthermore, it has been 
demonstrated that HPV-16-positive VIN patients with a pre-existing HPV-specific type 
1 T-cell response are more likely to have a strong response to imiquimod treatment.27 
Consequently, it has been suggested to combine imiquimod with HPV vaccination. 
In 19 VIN patients treated with imiquimod for 8 weeks followed by three doses of 
therapeutic HPV vaccination, complete histologic regression was observed in 32% 
of women at week 10, increasing to 58% at week 20 and 63% at week 52.26 These 
results are promising, but results of long-term follow-up are still needed.
In summary, our data indicate that treatment with imiquimod is an effective 
long-term therapy for VIN. Small lesions are more likely to respond completely to 
imiquimod treatment; therefore treatment period in the initial RCT might have been 
too short to be effective for larger lesions. Consequently we advise prolonging the 
treatment period until regression has stopped. Finally, despite these positive results, 
yearly follow-up visits are still recommended until larger studies have definitively 
demonstrated the long-term effects and recurrence rate after imiquimod treatment 
of HPV-induced VIN.
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aBstract
recently, we reported on the efficacy of imiquimod for treatment 
of usual type vulvar intraepithelial neoplasia (uvIn). a histologic 
regression of uvIn to normal tissue was observed in 58% of patients. 
as success of treatment is related to clearance of high-risk human 
papillomavirus (hpv), the aim of our study was to assess differences 
in immune cell counts and in the expression of p16InK4a in vIn tissue 
before and after imiquimod treatment, in relation to hpv clearance 
and clinical response.
vulvar tissue samples taken prior to imiquimod treatment and 
4 weeks after treatment were tested for the presence of hpv. 
previously determined immune cell counts (cd1a, cd207, cd208, 
cd123/cd11c, cd94, cd4, cd8 and cd25/hla-dr) in epidermis and 
dermis of 25 vIn patients and 19 healthy controls were completed 
with the counts for cd14 and cd68. the expression of p16InK4a was 
investigated by immunohistochemistry in 15 patients. 
Before imiquimod treatment, both hpv cleared and hpv 
non-cleared patients showed mainly in the dermis significantly 
upregulated immune cell counts compared to healthy controls. 
however, in patients that cleared hpv and showed histologic 
regression already 4 weeks after imiquimod treatment, immune cell 
counts and p16InK4a expression were normalized. 
In conclusion, our data indicate that imiquimod-induced clearance 
of hpv results in normalization of counts for certain immune cells 
and is strongly correlated with histologic regression of the disease. 
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IntroductIon
Vulvar Intraepithelial Neoplasia (VIN) is a premalignant disorder that is classified into 
differentiated	type VIN, which is associated with lichen sclerosus, and usual	type VIN 
(uVIN),1 which is caused by a persistent infection with a high-risk or oncogenic HPV 
(hrHPV, usually HPV-type 16, 18 or 33).2
Over the last decades, the incidence of uVIN has increased, most likely due to 
a rise in the incidence of HPV infections.3 Lifetime risk to become infected with HPV in 
western societies is around 80% and ~40% of all sexually active, female adolescents 
are at least once infected with hrHPV.4-7 When hrHPV persists (in less than 10% of 
cases), premalignant disorders of the anogenital tract, such as uVIN, can develop.8-10 
uVIN has invasive potential (10% of untreated cases will progress in 1-8 years) and 
needs to be treated proactively.11,12
The host immune response is of critical importance in determining clearance or 
persistence of an HPV infection. In natural life, during the early stages of a viral 
infection, CpG-rich regions in the viral DNA are recognized by toll-like receptor 
(TLR) 7 and 9 on the cell surface of immature dendritic cells (DCs). Upon binding, 
TLRs activate kinase cascades eventually activating NF-κB, which will result in the 
production of cytokines, adhesions molecules and other effectors of the innate 
immune response.13 Other receptor and adhesion molecules at the DC surface can 
bind viral antigen and will internalize and digest the antigen, which is followed by 
expression on the cell membrane in major histocompatibility complex (MHC) class 
I and in MHC class II. Class I MHC is recognized by CD8 and class II MHC by CD4. 
Upon binding antigen, the DC matures and migrates to the lymph nodes were it 
presents antigen bound to class II MHC, to naive T cells. Binding to naive T cells will 
result in production of memory and effector T cells, such as CD4+ T-helper cells, CD8+ 
cytotoxic T cells, or regulatory T cells (Treg cells).14,15
For a long time, surgical removal of all visible lesions was the standard treatment 
of uVIN.16 However, the concept that the immune response in uVIN is insufficient17-19 
has lead to new, less invasive treatment options in which the immunomodulator 
imiquimod plays a role. Imiquimod is an immune response modulator that acts by 
activating the DC, thereby inducing secretion of proinflammatory cytokines and T-cell 
activation. This results in a profound tumor-directed cellular immune response.20-23 
Recently, our group reported in a placebo-controlled, double-blinded, randomized 
trial (RCT) on the efficacy of imiquimod treatment for uVIN.24 During this trial, patients 
were treated with imiquimod or placebo twice a week for a period of 16 weeks. 
An imiquimod-induced reduction in lesion size by ≥25% in 81% of patients was 
measured, while a complete response was observed in 35% of patients. Moreover, 
when we defined the histological diagnoses in accordance to the ISSVD guidelines1 in 
uVIN or normal tissue instead of VIN 1, 2 or 3, complete histologic regression of uVIN 
was observed in 58% of patients. 
Furthermore, our study put forward that reduction in lesion size was correlated 
to normalization of the numbers of immune cells.25 In the present study, this concept 
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was investigated further. Therefore, we retrospectively assessed correlations between 
numbers of immature, mature and plasmacytoid DCs, natural killer (NK) cells, 
monocytes, macrophages and T cells in vulvar skin of 25 patients with uVIN before 
and 4 weeks after imiquimod treatment with the degree of histological response 
and clearance of HPV. Data from 19 healthy women were used as reference values. 
We also studied the presence of p16INK4a in relation to HPV status before and after 
imiquimod treatment. P16INK4a is a member of the INK4a family of cyclin dependent 
kinase inhibitors and during a persistent hrHPV infection, the viral oncoproteins 
E6 and E7 can interfere with the cell cycle regulatory pathway, which results in 
overexpression of p16INK4a. Therefore, immunohistochemistry with p16INK4a is used as a 
diagnostic aid and positivity of p16INK4a is a surrogate marker for hrHPV infection.26-29 
In addition to our previous article in which it was observed that VIN patients 
have disturbed immune cell counts,30 we observed in the present study that already 
4 weeks after treatment, HPV clearance and subsequent normalization of p16INK4a 
expression indicates a full or almost complete clinical response and is characterized by 
normalization of counts for certain immune cells in the epidermis and dermis. 
materIal and methods
patients
For the immunohistochemical staining frozen tissue sections of 4-mm punch biopsies 
were used. Biopsies from 25 women with multifocal uVIN who participated in a 
placebo-controlled RCT25 were taken before treatment with imiquimod (at time = 0 
weeks) and 4 weeks after treatment with imiquimod (at time = 20 weeks). During this 
trial, patients were treated with imiquimod or placebo twice a week for a period of 
16 weeks. All biopsies were immediately frozen in liquid nitrogen and stored at –80ºC 
until further analysis. Furthermore, 19 women who underwent elective vulvar surgery 
for cosmetic reasons served as healthy controls. 
For staining with p16INK4a, formalin-fixed paraffin-embedded biopsies were used,25 
taken before and 4 weeks after imiquimod treatment. 
Histological diagnosis of all biopsy specimens was performed by two experienced 
gynecologic pathologists. In the previous study by van Seters et	al.,25 biopsy specimens 
were classified into VIN 1, 2 and 3. In the present study, biopsy specimens were 
classified uVIN according to the new ISSVD guidelines1 (previously VIN 2 or 3). In this 
classification VIN 1 no longer exists and is considered normal.
All frozen tissue samples were analyzed for the presence of the 14 most prevalent 
hrHPV-types by using a standard GP5+/6+ PCR enzyme immunoassay followed by 
reverse line blot analysis, as described previously.31 For reasons explained in the results 
section, two samples were also analyzed with the SPF10 DEIA/LiPA version 1 test, 
which is a more sensitive HPV test.32 The HPV detection limit of the SPF10 DEIA/LiPa 
is 65 bp, and it detects 25 different HPV genotypes. 
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Retrospectively, patients were divided into two groups, namely patients who 
cleared HPV (HPV cleared) and patient who did not clear HPV (HPV non-cleared) after 
imiquimod treatment. 
Medical Ethical Committees approved our study design and all women provided 
voluntarily written informed consent.
Immunohistochemical staining on frozen tissue sections
Immunohistochemical staining was performed on 6-μm-thick frozen tissue sections 
for the following markers: CD1a, classical marker for immature DCs/ Langerhans 
cells (Orthobiotech, Bridgewater, NJ); CD207, marker for immature DCs expressing 
Langerin (DCGM4; Beckman Coulter, Fullerton, CA); CD208, marker for mature DCs 
(104.G4; Beckman Coulter); CD94, marker for NK cells (HP.3b1; Beckman Coulter); 
CD14, marker for monocytes (M0825; Dako Denmark, Glostrup, Denmark); CD68, 
marker for macrophages (M0718; Dako); CD4, marker for T-helper cells (MT.310; 
Dako); CD8, marker for cytotoxic T cells (DK25; Dako); CD25/HLA-DR, marker for 
Treg cells (AKT-1; Dako/1E5; Sanquin); for plasmacytoid DCs (CD123+/CD11c-), 
a double staining with both markers was used [anti-CD123 (9F5; Becton Dickinson, 
Alphen aan den Rijn, the Netherlands) and anti-CD11c (SHCL-3; Becton Dickinson)]. 
Staining and light microscopic evaluation of the obtained data were performed as 
described earlier.30
p16InK4a staining
Staining for p16INK4a was performed on 4-μm-thick paraffin-embedded tissue 
sections. The tissue sections were first deparaffinised overnight and rehydrated 
through graded series of xylene and alcohol. Endogenous peroxidase was blocked 
in H2O2 for 5 min, followed by washing the sections in dH2O. The slides were 
placed in a citrate buffer (pH 6) and heated in a 900 W microwave for 1 × 6.5 min, 
1 × 3 min and - after adding dH2O - again for 1 × 3 min. After cooling for 1 hr, 
tissues were washed in PBS for 3 × 5 min. Unspecific binding was blocked with 
200 μl PBS with 0.3% bovine serum albumin (BSA) for 30 min. Sections were then 
incubated overnight at 4˚C in a dark humid chamber with the mouse monoclonal 
antibody p16INK4a (clone JC8, sc-56330, Santa Cruz biotechnology, Inc., Santa Cruz, 
CA) in a dilution of 1:100. After incubation with the primary antibody, sections were 
incubated with 200 μl biotin-conjugated goat antimouse immunoglobulin (Dako) 
diluted 1:400 in PBS with 0.3% BSA for 30 min. This was followed by incubation 
with 200 μl streptavidin-biotinylated-peroxidase complex (ABComplex) with horse 
radish peroxidase (HRP) conjugate (Dako) for 30 min in dark. Between all incubation 
steps, sections were washed with PBS for 3 × 5 min. Staining was developed using 
0.133 g diaminobenzidine (DAB, Fluka, Sigma Aldrich, Buchs SG, Switzerland) in 200 
ml PBS with 600 μl H2O2 and the reaction was stopped after 10 min by washing in 
dH2O. Finally, sections were counterstained with haematoxylin (Klinipath, Duiven, 
the Netherlands) for 3 sec, washed with flushing water and dehydrated through 
graded series of alcohol and xylene.
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Light microscopic evaluation was performed blinded. Nuclear and cytoplasmic 
staining was considered as a positive reaction. Sections were scored semiquantitative 
for the percentage of p16INK4a positive cells: 0-25% positive (1), 25-50% positive (2), 
50-75% positive (3), >75% positive (4). Sections were also scored for the intensity 
of the staining: absent (1), light (2), moderate (3) and strong (4).33 The total score per 
sample was obtained by multiplying percentage with intensity.
statistical analysis
Data analysis was performed with the use of the SPSS 15.0 software package for 
Windows. The Kolmogorov-Smirnov test was used to identify the distribution for 
the cell types. Because a non-normal distribution was observed for some cell types, 
the non-parametric Mann-Whitney test was used for evaluation of differences in 
cell counts between the following groups: HPV cleared vs. healthy controls, and 
HPV non-cleared vs. healthy controls, both before and after imiquimod treatment. 
Differences in p16INK4a expression before and after treatment within the HPV cleared 
and HPV non-cleared VIN patients were assessed with the use of the Wilcoxon signed 
rank test. 
The Mann-Whitney test was used to assess differences between the HPV cleared 
and HPV non-cleared patients. A two-tailed P-value of P<0.05 was chosen to represent 
statistical significance.
results
patients
The median age of the 25 VIN patients was 39 years (range, 22-56 years). In the healthy 
control group, the median age was 40 years (range, 19-56 years). Cryosections were 
obtained from al these patients, but paraffin-embedded samples were limited and 
only obtained from 15 of 25 VIN patients before as well as after treatment.
Twenty-three patients were smokers, two patients had a history of 
immunosuppressant use, and 14 patients had a history of CIN. Patients had not 
received any treatment for at least 3 months before treatment with imiquimod. Of all 
controls, six were smokers and six had a history of smoking, none of the controls had 
a history of immunosuppressant use and none of them had a history of CIN. 
histological response and presence of hpv dna and p16InK4a
Before imiquimod treatment, 19 of the 25 VIN patients were positive for HPV 16, 
five patients were positive for HPV 33, and one patient was HPV DNA-negative.25 
The HPV DNA-negative patient was excluded from further analysis. Four weeks after 
imiquimod treatment, seven patients were positive for HPV 16, three were positive 
for HPV 33 and 14 patients were HPV DNA-negative. All healthy controls were HPV 
DNA-negative. 
Immunohistochemical analysis for p16INK4a expression was performed on tissue 
sections from 15 patients before and after imiquimod treatment. Before treatment, 
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12 of 15 patients were HPV 16 positive and three patients were HPV 33 positive. 
After treatment, four patients were HPV 16 positive, two were HPV 33 positive and 
nine patients were HPV DNA-negative.
P16INK4a scores and staining before and after treatment in relation to histologic 
regression and viral clearance are shown in Table 1 and in Figure 1. Median score of 
p16INK4a expression (percentage × intensity) before imiquimod treatment was 12 for 
the HPV cleared and 12 for the HPV non-cleared patients. After treatment, p16INK4a 
expression was significantly decreased in HPV cleared patients (P=0.008) but not in 
HPV non-cleared patients (P=0.084). In addition, p16INK4a score after treatment was 
significantly lower in HPV cleared patients compared to HPV non-cleared patients 
(P=0.006). Interestingly, two patients who cleared HPV were still diagnosed with 
uVIN after treatment and additional observations and experiments were performed 
to clarify this situation. 
Patient one had a clinical response to imiquimod treatment of 76-99% and was 
negative for HPV and for p16INK4a expression as measured in a biopsy obtained 4 
weeks after treatment. The patient was followed for an additional period after which 
it was observed that at that point all lesions had disappeared. To date (>5 years), this 
patient is still disease-free. 
Patient two had a clinical response to imiquimod treatment of less than 25%, and 
remained positive for p16INK4a, although the HPV test indicated clearance of the virus. 
Follow-up of this patient showed several recurrences after imiquimod treatment. To 
rule out the possibility of having missed an HPV infection, a different more sensitive 
HPV test was performed (SPF10 DEIA/LiPA version 132). Using this sensitive HPV test 
for both patients we could not detect the presence of HPV viral DNA, signifying the 
absence of hrHPV infection.
table 1. histologic diagnosis after imiquimod treatment and p16InK4a scores in hpv cleared 
and hpv non-cleared patients before and after imiquimod treatment.
diagnosis  
after 
treatment
hpv cleared hpv non-cleared
n p16
InK4a before
median (range)
p16 InK4a after
median (range) n
p16 InK4a before
median (range)
p16 InK4a after
median (range)
uVIN 2 10.5 (9-12) 3.5 (1-6) 6 12 (12-16) 8 (2-16)
normal 7 12 (6-16) 2 (1-3) 0 - -
All patients 9 12 (6-16) 2 (1-6)1 6 12 (12-16) 8 (2-16)2
1Significant different compared to before treatment, P=0.008
2Not significantly different compared to before treatment, P=0.084
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evaluation of immune cell numbers in vIn lesions before and after 
imiquimod treatment and in normal vulvar skin
epidermis. Immunohistochemical analysis of the epidermis showed significant 
differences in immune cell counts between HPV cleared (n=14) or non-cleared (n=10) 
VIN patients and controls (n=19) (Table 2). 
Before treatment, CD8+ cytotoxic T cells were significantly lower in HPV cleared 
patients as compared to controls (Table 2, P-value 1 vs. 2), while CD14+ monocytes 
were higher in HPV cleared patients and in HPV non-cleared patients compared to 
healthy controls (Table 2, P-value 1 vs. 2 and P-value 1 vs. 4). After treatment, counts 
for CD8+ and CD14+ cells returned to control levels in HPV cleared patients (Table 2, 
P-value 1 vs. 3, Figs. 2a, 2b, and 3), while in HPV non-cleared patients the elevated 
CD14+ cell numbers did not return to control levels (Table 2, P-value 1 vs. 5). In 
addition, CD123+/CD11c- pDCs, CD208+ mDCs and CD68+ macrophages were also 
significantly higher in HPV non-cleared patients after treatment compared to controls 
(Table 2, P-value 1 vs. 5).
CD1a+ Langerhans cells in HPV cleared and non-cleared patients were not different 
from healthy controls before treatment, but were significantly higher in HPV cleared 
patients after treatment (Table 2, P-value 1 vs. 3).
A
ED
CB
Figure 1
Figure 1. P16INK4a expres-
sion in control tissue and 
in VIN lesions before and 
after imiquimod treatment. 
A. hrHPV negative control 
tissue does not show 
expression of p16INK4a. B, C. 
p16INK4a expression before 
(B) and after (C) imiqui-
mod treatment in a patient 
that did show clearance of 
HPV. d, e. p16INK4a expres-
sion before (D) and after 
(E) imiquimod treatment in 
a patient that did not clear 
HPV (photographs A-E, 
magnification: ×10).
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No significant differences before treatment were seen when we compared the HPV 
cleared patients with HPV non-cleared patients (Table 2, P-value 2 vs. 4). However, 
when we performed the same analysis after treatment, the number of CD14+ and 
CD68+ cells were significantly higher in the HPV non-cleared group (Table 2, P-value 
3 vs. 5).
dermis.	 In the dermis, differences in cell numbers were much more pronounced 
(Table 3). Before imiquimod treatment, there were significantly higher numbers of 
CD4+ T-helper cells, CD8+ cytotoxic T cells, CD25/HLA-DR+ Treg cells, CD208+ mDCs 
Figure 2. Numbers of immune cells in control and VIN tissues before and after imiquimod treatment 
in patients who cleared or did not clear HPV from the site of the lesion. A, B. CD8+ and CD14+ cells 
in epidermis of VIN patients before and after imiquimod treatment. C – F. CD208+, CD123+/11c-, 
CD4+ and CD8+ cells in dermis of VIN patients before and after imiquimod treatment. Median ± SD. 
*P<0.05, **P<0.005, ***P<0.001, significant different from controls (Mann-Whitney test).
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Figure 3
CD14 CD4 CD8
Control
VIN Before, 
HPV cleared
VIN After, 
HPV cleared
VIN Before, 
HPV not 
cleared
VIN After, 
HPV not
cleared
Figure 3.	CD14, CD4 and CD8 positive cells in control and VIN tissues before and after imiquimod 
treatment in patients who cleared or did not clear HPV from the site of the lesion (magnification: 
×10).
and CD123+/CD11c- pDCs in HPV cleared patients vs. controls (Table 3, P-value 
1 vs. 2). Also in the HPV non-cleared group, the numbers of these cells were higher, 
although this was not significant for CD123+/CD11c- pDCs and CD25/HLA-DR+ Treg 
cells (P=0.079, P=0.082 respectively, Table 3, P-value 1 vs. 4). In the dermis, similar 
to the epidermis, in HPV cleared patients cell numbers returned to normal after 
treatment (Table 3, P-value 1 vs. 3), this in contrast to the cell numbers in HPV non-
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cleared patients that did not return to normal (Table 3, P-value 1 vs. 5, Figs. 2c-2f 
and 3). 
When we compared HPV cleared and HPV non-cleared patients, no significant 
differences in cell counts were seen before treatment (Table 3, P-value 2 vs. 4), 
while after treatment, CD208+, CD8+, CD4+, CD94+, CD14+ and CD68+ cells were 
significantly lower in the HPV cleared patients in comparison to the HPV non-cleared 
patients (Table 3, P-value 3 vs. 5).
Individual values for immune cell counts per patient, combined with the data 
on viral clearance and p16INK4a expression, are shown in the supplementary Table 1 
(http://www.erasmusmc.nl/47393/1584119/1603959/Terlou).
dIscussIon
The observations in our study demonstrate that clearance of HPV infection already 4 
weeks after treatment with imiquimod, results in normalization of immune cell counts 
and normalization of p16INK4a expression at the site of the lesion. Winters et al.34 also 
studied immune cell counts and measured the HPV status of VIN patients before 
and after treatment with imiquimod combined with photodynamic therapy (PDT). 
Interestingly, Winters observed that besides all complete responders, 2 of 4 partial 
responders and one patient with stable disease had become HPV DNA negative. In 
our study, 12 of 14 patients that cleared HPV 4 weeks after imiquimod treatment 
showed complete histologic regression of uVIN and an additional patient showed 
a somewhat delayed complete regression. An explanation for the delayed regression 
could be that clearance of HPV precedes regression of uVIN. This has been shown 
previously in patients with abnormal cervical smears, in which hrHPV clearance 
preceded regression of cervical lesions by an average of 3 months.35 
Another patient, who cleared HPV after treatment, however, showed a clinical 
response of less than 25% and continuing elevated expression of p16INK4a. Our first 
thought was that the method used to detect viral DNA was not sensitive enough. 
However, even a more sensitive method on paraffin sections adjacent to those used 
for p16INK4a detection could not detect HPV. In other words, despite imiquimod-
induced clearance of HPV the disease had only marginally improved and p16INK4a 
level remained elevated. These findings seem to indicate that in this particular case 
the disease may have progressed beyond HPV control. Elevation of p16INK4a, normally 
a hallmark of hrHPV,26-29 in this case can be considered a compensation for abnormal 
cell proliferation as is observed in many HPV-negative carcinomas.28,36,37 
hpv clearance results in normalization of immune cell counts
Since persistent HPV infection is the underlying cause of VIN and the host immune 
response is primarily directed against this HPV infection, we focused our investigations 
on differences in local immunity between patients who were able to clear HPV and 
patients who were not able to clear HPV upon local treatment with imiquimod. Our 
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most important finding is that, already 4 weeks after the end of treatment, imiquimod-
induced clearance of HPV results in normalization of the numbers of immune cells at 
the site of the lesion (Table 2 and 3). Although imiquimod treatment is generally well 
tolerated and for a number of patients a good alternative for otherwise mutilating 
treatments like vulvectomy or local excision, it is of interest to know beforehand 
which patients will respond to therapy and which patients will not. Winters et	
al.34 reported that Treg cells in nonresponders before treatment were significantly 
increased compared to numbers in responders, a finding which we could not confirm. 
However, we did compare the numbers of immune cells before treatment between 
those patients that cleared HPV upon treatment vs. those patients that did not clear 
HPV to find other possible predictors of HPV clearance upon imiquimod treatment. 
Our results demonstrate lower CD8+ cell numbers in the epidermis of patients that 
cleared HPV, but not in patients who did not clear HPV when we compared to healthy 
control levels (Table 2). Furthermore, CD123+ pDCs in the epidermis and CD68+ cells 
in the dermis of HPV non-cleared patients were significantly higher compared to 
controls (Table 2 and 3), which was not the case in the HPV cleared group. In theory, 
the above indicated CD-markers can be used to predict success or failure of imiquimod 
treatment to clear HPV. However, when we compared the HPV cleared group directly 
with the HPV non-cleared group (before treatment, Table 2 and 3, P-value 2 vs. 4), 
we did not measure any significant differences between the two groups. On the basis 
of our current findings we consider it too early to do any recommendations on the 
above markers to predict HPV clearance upon imiquimod treatment. 
Previously, our study group reported on the immunosuppressive state of the 
epidermis of VIN patients, demonstrated by a decrease in CD1a+ and CD8+ cells.30 
Interestingly, the present study shows a higher number of CD14+ monocytes in 
the epidermis of VIN patients compared to controls. It is known that CD14+ cells 
in an environment rich of TGF-β1 (which is produced by most immune cells), and 
in response to CCL20 (for which CD14+ cells express the receptor molecule CCR6) 
differentiate into immature Langerhans cells (CD207+). Under conditions of cutaneous 
inflammation, when the proinflammatory cytokine GM-CSF is released along with 
TGF-β1, CD14+ cells can differentiate into mature Langerhans cells (CD1a+).38-41 This is 
in accordance with our findings. After treatment, we observed a decreased number of 
CD14+ monocytes (P=0.005, Wilcoxon signed rank test) in the HPV cleared epidermis, 
while the number of CD1a+ Langerhans cells in this group seemed to be increased 
(P=0.074, Wilcoxon signed ranked test). During successful imiquimod treatment, 
CD14+ monocytes in the epidermis might have differentiated into Langerhans cells.
An important limitation of the present study is the absence of biopsy specimens 
during treatment to assess the specific changes in immune cells induced by imiquimod 
that are associated with the clearance of lesions. Such data would be important in 
identifying the specific immune cells that must be targeted for successful treatment.
In conclusion, our data indicate that already 4 weeks after the end of treatment, 
imiquimod-induced clearance of HPV (confirmed by normalization of p16INK4a 
expression) results in normalization of immune cell counts and is strongly correlated 
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with histologic regression of the disease. Interestingly, van Seters et	al.24 could show 
that histologic regression is maintained till at least one year after the start of treatment 
and preliminary long-term follow-up data (>5 years) further confirm the success of 
imiquimod treatment.
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aBstract
Imiquimod has been shown to be an effective treatment for usual type vulvar 
intraepithelial neoplasia (uvIn). since local inflammation and burning are 
common side effects, patients often use nonsteroidal anti-inflammatory 
drugs (nsaIds). our study investigated whether nsaId-use, which has been 
documented to inhibit the cell-mediated immune response, interferes with 
the outcome of imiquimod treatment.  
monocyte-derived dendritic cells (modcs) and langerhans cells (molcs) 
were cultured in the presence of nsaIds. the expression of relevant surface 
markers (cd80, cd86, cd40, hla-dr, ccr6 and ccr7), stimulatory function, 
and cytokine production were evaluated. furthermore, we analyzed in uvIn 
patients whether frequent nsaId-use had an effect on the clinical response 
and on immunocompetent cell counts before and after imiquimod treatment. 
although an effect was observed on the expression of modc and molc 
maturation markers, nsaIds did not affect the ability of modcs and molcs to 
stimulate allogeneic t-cell proliferation, or the production of cytokines in an 
allogeneic t-cell stimulation assay.  In agreement with this, in uvIn patients 
treated with imiquimod, no interference of frequent nsaId-use with clinical 
outcome was observed. however, we did notice that high cd1a+ and cd207+ 
cell counts in frequent nsaId-users before treatment seemed to predict a 
favorable response to imiquimod treatment.
our data indicate that nsaId-use does not seem to interfere with modc 
and molc function and does not interfere with immunomodulatory properties 
of imiquimod in uvIn patients. therefore, nsaIds can safely be used to reduce 
imiquimod side effects in uvIn patients during treatment.
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IntroductIon
Usual type Vulvar Intraepithelial Neoplasia (uVIN) is a premalignant skin disorder, 
which is caused by a persistent infection with high-risk human papillomavirus 
(hrHPV).1,2 In the etiology of uVIN, inhibition of the host immune response seems to 
be an important determinant. Earlier studies demonstrated that immunodeficiency 
and smoking (which reduces local immunity) are important risk factors for the 
development of HPV-related premalignant and malignant lesions.3-7 
The concept that the immune response is insufficient in patients with uVIN has 
lead to treatment with the immune response modifier imiquimod. Imiquimod binds 
to toll-like receptor (TLR) 7 and 8 at the cell surface of dendritic cells (DCs). Binding 
induces consecutive activation of nuclear factor-kappa B (NF-κB). This activation 
results in secretion of multiple cytokines, such as TNFα, type-1 IFN and IL-12, and 
activation of DCs, thus inducing a strong cellular immune response.8,9 Upon treatment 
of uVIN with imiquimod, 35% of patients had a complete response (100% reduction 
in lesion size),10 which lasted for >5 years in all but one case.11 In addition, another 
46% of patients showed a partial reduction in lesion size of at least 25%. Only in 
patients where the numbers of immunocompetent cells were normalized, the clinical 
response was ≥75%.10 Based on these results, imiquimod is now considered first-line 
treatment for uVIN in the Netherlands. 
Treatment with imiquimod, however, is not always tolerated well. Patients using 
imiquimod frequently complain of side effects such as severe local inflammation, 
itching or burning, flulike symptoms, weariness and headache.10,12 We observed that 
patients treated with imiquimod commonly use nonsteroidal anti-inflammatory drugs 
(NSAIDs) or paracetamol in order to reduce these side effects. NSAIDs have been 
described to inhibit the enzymatic activity of cyclooxygenase (COX) 1 and 2, thereby 
impairing the conversion of arachidonic acid to prostaglandins (PGs), which results in 
an anti-inflammatory effect.13 Additionally, several studies demonstrated that NSAIDs 
also suppress NF-κB activation14-18 and in this way can inhibit DC differentiation.14,19-20 
The effects of concomitant use of NSAIDs during imiquimod treatment are 
unknown. However, since the function of imiquimod is to enhance the patients’ cell-
mediated immune response against HPV and thus cure uVIN, the aim of this study was 
to investigate whether NSAIDs have an inhibitory effect on the cell-mediated immune 
response and thereby can interfere with imiquimods immunomodifying activities. 
Because it is not possible to isolate enough immune cells from VIN biopsies, we 
cultured DCs and Langerhans cells (LCs, a specialized dendritic cell that populates the 
epidermis21) from peripheral blood mononuclear cells (PBMCs) to elucidate the effect 
of NSAIDs on differentiation and function of antigen presenting cells. Furthermore, in 
patients who participated in an earlier study,10 we analyzed whether frequent use of 
NSAIDs had an effect on imiquimod response and on immunocompetent cell counts 
before and after imiquimod treatment. 
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materIal and methods
Isolation of cd14+ cells and culture of modcs and molcs
PBMCs were isolated from buffy coats of healthy donors by Ficoll-paque (Ficoll Paque 
Plus, GE Healthcare Biosciences, Uppsala, Sweden) centrifugation. After isolation, 
PBMCs were washed and CD14 microbeads (MACS Microbeads, Miltenyi Biotec, 
Bergisch Gladbach, Germany) were added to isolate CD14+ cells. The CD14+ fraction 
was counted and the monocytes were placed in 24 well plates at a density of 1×106 
cells/ml/well. Monocytes were cultured in RPMI 1640 containing Glutamax (Gibco 
Invitrogen, Carlsbad, USA), supplemented with 10% FCS and gentamycin, at 37˚C in 
a humidified atmosphere containing 5% carbon dioxide. Growth factors used for the 
generation of moDCs were 1,000 IU/ml GM-CSF (Immunotools, Friesoythe, Germany) 
and 200 IU/ml IL-4 (R&D systems, Abingdon, UK). TGF-β1 (10 ng/ml, PeproTech, 
Rocky Hill, USA) was added to moDC cultures to generate moLCs.21,22 On day two 
of culture, 0.5-2.5 mM aspirin (Sigma, Zwijndrecht, the Netherlands), 100-500μM 
ibuprofen (Sigma) or ethanol (Sigma) was added to the wells to measure the effect of 
aspirin or ibuprofen on moDC and moLC maturation. On day 6, cells were stimulated 
with 2 ng/ml CPG 1668 (Gibco) to mimic viral infection.
fluorescence-activated cell sorting (facs) analysis
On day 7, cells were harvested and the expression of membrane markers was 
assessed by flowcytometry using the following fluorescent labeled antibodies: CD11c 
APC, HLA-DR  APC-Cy7 for moDC culture and HLA-DR PE-Cy7 for moLC culture (all 
BD Biosciences, Franklin Lakes, USA), CD1a PE-Cy5, CD14 APC, CD80 PE (all BD 
Pharmingen, San Diego, USA), CD207 PE (Immunotech, Marseille, France), CD40 
APC, CD86 PE (both eBioscience, Hatfield, UK), CCR7 FITC and CCR6 FITC (both 
R&D systems). Cells were labeled according to the manufacturers’ instructions and 
appropriate isotype-matched antibodies served as negative controls. After staining 
with the viability marker 4',6-diamidino-2-phenylindole (DAPI, Invitrogen Molecular 
Probes, Carlsbad, USA), cells and data were analyzed using the LSR II (BD Biosciences) 
and FlowJo software (Treestar, Ashland, USA).
Isolation and fluorescent labeling of naive cd4+ t cells
T cells were purified from human buffy coat. Naive T cells were obtained by negative 
selection using naive CD4+ T-cell isolation kit (Miltenyi) according to manufacturers’ 
instructions. All steps were performed with MACS buffer (PBS supplemented with 
5 mM EDTA and 1% BSA) at 4°C. In brief: all cells, except CD4+ naive T cells, were 
indirectly magnetically labeled with a cocktail of biotin-conjugated antibodies (CD8, 
CD14, CD16, CD19, CD36, CD45RO, CD123, TCRγ/δ and Glycophorin A) followed 
by incubation with antibiotin microbeads. Isolation of pure naive T cells was achieved 
by depletion of the magnetically labeled non-CD4+ naive T cells. For fluorescent cell 
labeling, cells were washed twice with serum-free medium and labeled in a final 
concentration of 5 μM carboxyfluorescein succinimidyl ester (CFSE)	 (Invitrogen, 
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Molecular Probes) for 10 min in serum-free medium at 37°C. Adding excess ice-cold 
culture medium stopped the reaction.  
allogeneic mixed lymphocyte reaction (mlr)
CFSE labeled and CFSE nonlabeled allogeneic peripheral blood naive T cells were co-
cultured in duplicate with moDCs or moLCs with and without NSAIDs with a DC:T-cell 
ratio of 1:10 in culture medium in 96 well round bottom plates for 5 days at 37°C. At 
day 5, T cells were harvested and stained with the antibodies CD4 APC (eBioscience) 
and CD3 PE (BD Pharmingen) to discriminate between T cells and moDCs or moLCs. 
T-cell proliferation was measured by flowcytometry using a LSR II (BD Biosciences) and 
FlowJo software (Treestar). 
measurement of prostaglandin e2 and cytokine production
Levels of prostaglandin E2 (PGE2) were measured in day 7 supernatant of moDC and 
moLC cultures by using a competitive enzyme immunoassay (R&D systems) according 
to the manufacturer’s instructions.
Cytokine levels were measured in MLR culture supernatants (moLCs cultured with 
T cells) using ELISA kits according to the manufacturer’s instructions. Il-4, IFNγ, type 1 
IFN, TNFa (all eBioscience) and IFN-inducible protein-10 (Ip-10, BD Biosciences), were 
measured in day 5 supernatant of allogeneic MLR. 
study population and immunohistochemical staining of biopsies
Twenty-five women with multifocal uVIN who participated in our double-blinded, 
placebo-controlled randomized clinical trial (RCT)10 were treated with imiquimod 
twice a week for 16 weeks. Biopsy samples of these patients taken before and 4 
weeks after treatment were analyzed for the presence of CD1a+ LCs, CD207+ DCs 
expressing Langerin, CD208+ DCs, CD123+/CD11c- plasmacytoid DCs, CD94+ natural 
killer (NK) cells, CD14+ monocytes, CD4+ T-helper cells, CD8+ cytotoxic T cells, CD25+/
HLA-DR+ regulatory T cells, and CD68+ macrophages, as described previously.23
All patients kept a daily record chart to report use of their study medication as 
well as any concomitant medication. Drugs most commonly used in this study were 
over-the-counter NSAIDs. All patients who were treated with imiquimod were divided 
into two groups according to the following criteria for the frequency of NSAID-use: 1) 
Low users: never or sporadically, i.e. no more than three times during the whole study 
period for one or two days, and 2) frequent users: daily or regularly, i.e. more than 
three times during the whole study period, for 1 up to 5 days in a row.
statistical evaluation
Data analysis was performed with the use of the SPSS 15.0 software package for 
Windows. For the in-vitro experiments, differences in cytokine levels and in percentage 
of proliferated T cells between groups were compared using the Kruskal-Wallis test. 
We used the Fisher Exact test to evaluate differences in NSAID-use between patients 
with ≥75% clinical response, defined as a clinical reduction in lesion size of at least 
75%, versus patients with <75% clinical response, defined as a clinical reduction in 
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lesion size of less than 75%. We used the Mann Whitney U test to evaluate differences 
in immunocompetent cell counts between the different subgroups (frequent- or low 
NSAID-users with ≥75% response versus <75% response). A two-tailed P-value of 
P<0.05 was chosen to represent statistical significance.
results
In vitro effect of aspirin and ibuprofen on modc maturation and on 
modc induced t-cell proliferation 
To investigate the effect of aspirin and ibuprofen on moDC maturation, CD14+ 
monocytes (+ GM-CSF and IL-4) were cultured from day 2 till day 7 in the presence 
of 0.5-2.5mM aspirin or 100-500μM ibuprofen as described in Materials	 and	
Methods. Since uVIN patients have a permanent HPV-infection, we added CPG on 
day 6 to mimic the stimulatory effect of viral DNA and detect the effect on moDC 
maturation and function. We performed a competitive immunoassay on day 7 culture 
supernatants to demonstrate that NSAIDs reduced PGE2 levels. PGE2 production was 
reduced by more than 20% after stimulation with ibuprofen and by more than 70% 
after stimulation with aspirin (data not shown).
After FACS analysis on day 7, living (DAPI-negative) moDCs (CD11c+, HLA-DR+ 
cells) were gated (Fig. 1a). From these viable cells, we analyzed the expression of the 
maturation markers CD80, CD86, CD40, and HLA-DR and of the chemokine-receptors 
CCR6 (highly expressed in immature DCs24) and CCR7 (highly expressed in mature 
DCs24). As shown in Figure 1b, a dose-dependent increase in expression of HLA-DR and 
CD86 was observed upon stimulation with aspirin or ibuprofen, while CD80, CD40 and 
CCR6 expression was somewhat decreased upon stimulation with the highest dose of 
aspirin or ibuprofen. No difference in expression was observed for CCR7. Similar results 
were observed in cell cultures without CPG stimulant (data not shown).  
In order to investigate whether interaction of NSAID-treated moDCs with CD4+ 
T cells results in T-cell activation, we co-cultured moDCs with allogeneic T cells and 
subsequently analyzed T-cell proliferation. First, living CD4+CD3+ T cells were gated 
and the percentage of proliferated cells was analyzed by gating the CFSE-negative 
T-cell population (Fig. 1c). Figure 1d shows the percentage of proliferated T cells in 
co-cultures with moDCs stimulated with CPG, CPG + 2.5 mM aspirin or with CPG 
+ 500 μM ibuprofen. MoDCs stimulated with CPG in the presence or absence of 
ibuprofen or aspirin did not differ significantly in their ability to activate T cells.
effect of aspirin and ibuprofen on molcs
Our next step was to investigate the effect of NSAIDs on moLCs, since LCs play a 
major role in initiation of the cellular immune response in the skin.25 Previously, we 
observed that LC counts are reduced in the epidermis of VIN patients.23
In order to investigate the effect of NSAIDs on moLCs, we cultured PBMCs with 
GM-CSF, IL-4 and TGF-β to generate a high percentage of Langerhans-like moDCs. As 
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is shown in Figure 2a, CD1a - a cell-specific marker for epidermal LCs25 - is expressed 
on the surface of cells cultured with TGF-β. However, upon stimulation with aspirin or 
ibuprofen, more cells became CD1a negative suggesting an impaired differentiation. 
The strongest effect was observed after stimulation with ibuprofen. The expression 
of CD207  - Langerin, which is a LC specific C-type lectin25  - decreased upon 
aspirin stimulation but increased upon ibuprofen stimulation. When we measured 
the expression of the maturation markers CD80, CD86 and HLA-DR, an increase in 
CD86 expression was found upon stimulation with aspirin or ibuprofen (Fig. 2a), 
as was observed in conventional moDCs. However, HLA-DR expression increased 
upon stimulation with ibuprofen, but decreased upon stimulation with aspirin. CCR6 
increased upon ibuprofen stimulation and no differences were found for the other 
markers (Fig. 2a).
To assess the effect of NSAID-stimulated moLCs on T-cell proliferation, we performed 
again an allogeneic MLR. However, moLCs cultured with or without ibuprofen or 
aspirin did not differ significantly in their ability to activate T cells (Fig. 2b). 
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Figure 1. A. Gating of monocyte-derived dendritic cells (moDCs). DAPI-negative living cells are gated 
and from this population, CD11c+ HLA-DR+ cells are selected as moDCs. B. Expression of HLA-DR, 
CCR6, CD86, CD80, CCR7 and CD40 in moDCs ± aspirin (Asa) and expression in moDCs ± ibupro-
fen (Ibu). C.	Gating of proliferated T cells. CD4+CD3+ cells are selected as T cells. Proliferated T cells 
are CFSElow. d. Percentage of proliferated T cells in co-cultures with moDCs stimulated with CPG, 
with CPG + ibuprofen 500 μM (Ibu500) and with CPG + aspirin 2.5 mM (Asa2.5). No significant 
differences were observed between CPG, CPG + ibuprofen and CPG + aspirin (Kruskal-Wallis test). FSC, 
forward scatter; SSC, sideward scatter; CFSE, carboxyfluorescein succinimidyl ester; Asa, aspirin; Ibu, 
ibuprofen.
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The levels of different inflammatory cytokines were measured in supernatant of 
MLR cultures to assess the effect of NSAIDs on cytokine production. Although, Ip-10 
and Il-4 were significantly higher in MLR supernatants than in T cells cultured without 
moLCs, no effect of aspirin or ibuprofen was observed on cytokine production (Fig. 2c).
In vivo effect of nsaId-use on immunocompetent cell counts before 
and after imiquimod treatment, and response rate after treatment
Results from our in-vitro experiments demonstrated no effect of NSAIDs on phenotype 
and function of moDCs and moLCs. Because we were interested in a possible 
interference of NSAIDs with imiquimod treatment, we next investigated the effect of 
NSAID-use on imiquimod response in VIN patients who were treated with imiquimod 
Figure 2. A. Expression of CD207, CD1a, HLA-DR, CCR7, CD80, CCR6 and CD86 in monocyte-
derived Langerhans cells (moLCs) ± aspirin (Asa) and expression in moLCs ± ibuprofen (Ibu). B. Per-
centage of proliferated T cells in co-cultures with moLCs with CPG, CPG + ibuprofen 500 μM (Ibu500) 
and with CPG + aspirin 2.5 mM (Asa2.5). No significant differences were observed between CPG, 
CPG + ibuprofen and CPG + aspirin (Kruskal-Wallis test). C. Cytokine production measured in alloge-
neic MLR supernatants with moLCs and T cells. Mean ± SEM, data from four buffy coats. No differ-
ences between CPG, CPG + aspirin 2.5 mM and CPG + ibuprofen 500 μM (Kruskal-wallis test). Asa, 
aspirin; Ibu, ibuprofen.
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in a previous double-blinded, placebo-controlled RCT.10 According to our definition, 
12 of 25 patients were frequent NSAID-users; 5 of the 12 had a clinical response to 
imiquimod of ≥75% and seven patients had a response of <75%. Thirteen patients 
were low NSAID-users; eight of them had a clinical response of ≥75% response and 
five patients had a response of <75%. No significant difference was measured in 
NSAID-use between patients with ≥75% response and patients with <75% response. 
This indicates that NSAID-use does not influence the success of imiquimod treatment. 
Interestingly, when we compared immunocompetent cell counts between different 
subgroups, we did observe that frequent NSAID-users with ≥75% response had 
significantly higher CD1a+ and CD207+ cell counts in the epidermis before imiquimod 
treatment than frequent NSAID-users with <75% response (P=0.007 and P=0.004 
respectively, Fig. 3a and 3b) or than any of the low NSAID-users. Cell counts for the 
different immunocompetent cells are shown in supplementary Table 1 (http://www.
erasmusmc.nl/47393/1584119/1603959/Terlou). 
In conclusion, elevated CD1a+ and CD207+ cell counts in frequent NSAID-users 
seem to predict a good clinical response to imiquimod treatment, but NSAID-use, as 
such, does not negatively affect the success of imiquimod treatment. 
Figure 3 
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Figure 3. Number of 
CD1a+ and CD207+ 
cells before and after 
imiquimod treatment 
in frequent NSAID-
users and low NSAID-
users with ≥75% and 
<75% clinical response. 
Frequent NSAID-users 
with ≥75% response 
have significantly higher 
CD1a+ and CD207+ cell 
counts in the epider-
mis before imiquimod 
treatment than frequent 
NSAID-users with <75% 
response (P=0.007 and 
P=0.004, Mann-Whitney 
U Test). 
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dIscussIon
In our study, we investigated whether NSAIDs have an inhibitory effect on the 
cell-mediated immune response and thereby can interfere with imiquimods 
immunomodifying activities. For this purpose, moDCs and moLCs were cultured in	
vitro in the presence of aspirin and ibuprofen and expression of relevant surface 
markers, stimulatory function and production of proinflammatory cytokines were 
measured. Although an effect was observed on the expression of moDC and moLC 
maturation markers (HLA-DR, CD86, CD80, CD40, and CCR6), NSAIDs did not affect 
the ability of moDCs and moLCs to stimulate T cells, neither could we observe an 
effect on the production of cytokines. Additionally, we investigated whether frequent 
use of NSAIDs had an effect on imiquimod response in patients with uVIN. We 
found that frequent NSAID-users with high CD1a+ and CD207+ cell counts before 
imiquimod treatment had a favorable response to imiquimod treatment. In other 
words, in frequent NSAID-users high CD1a+ and CD207+ cell counts seem to predict 
the imiquimod response. However, in accordance with our in	vitro findings, we did 
not observe a reduced imiquimod response in VIN-lesions of frequent NSAID-users. In 
summary, our results indicate that NSAIDs do not inhibit moDC and moLC stimulatory 
function and do not seem to interfere with imiquimods immunomodulatory properties 
in uVIN patients.
NSAIDs have been used for more than 100 years to reduce pain and inflammation, 
in particular in patients with various rheumatologic and inflammatory disease states 
for adequate control of their condition. The anti-inflammatory and analgesic efficacy 
of NSAIDs is mainly due to the inhibition of COX-1 and COX-2, which convert 
arachidonic acid to PGs.13 PGs play an important role in the function of immune 
cells by modulating production of cytokines, chemokines and their receptors.26 
Additionally, PGs such as PGE2 are mandatory for DC migration
27,28 and enhance T-cell 
proliferation and differentiation.29 
Another way in which NSAIDs affect the immune response is by inhibiting NF-κB 
activation.14 NF-κB has been regarded as a key element in the response of cells to 
inflammatory stimuli and targets proinflammatory cytokines, chemokines and cell 
adhesion molecules.16 Inhibition of NF-κB also affects maturation of DCs.30 Several 
studies have investigated the effect of NSAIDs on DCs.19,20, 31-35 Hackstein et	 al.19 
reported an inhibition of maturation and function of murine DCs after stimulation with 
aspirin, while Matasic et	al.20 also demonstrated an impairment of immunostimulatory 
function in human DCs after aspirin stimulation. This effect was due to inhibition of 
NF-κB, since no effect was observed upon stimulation with selective COX-1 or COX-2 
inhibitors.20 In contrast, other studies demonstrated that NSAIDs can stimulate DC 
function by inhibition of PGE2 production. PGE2 enhances Il-10, which down-regulates 
Il12-p70 production and thereby down-regulates DC stimulatory capacity.34,35 These 
sometimes contradictory reports are difficult to compare, since different cell types, 
protocols or drugs were used. Moreover, various pathways involved in DC maturation 
can be affected upon stimulation with NSAIDs.
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In our study, no effect on moDC function was measured after stimulation with 
aspirin or ibuprofen, despite the fact that the concentrations of aspirin and ibuprofen 
used in our experiments were within the range to inhibit COX-1, COX-2 and NF-κB 
activation.17,18 In addition, we also failed to observe an effect of NSAID-use during 
imiquimod treatment of VIN. A possible explanation for this is that a significant 
percentage of NSAIDs bind to plasma albumin, and in	vivo NSAIDs are partly converted 
into more or less biologically active metabolites,16,36 which could result in plasma 
concentrations of NSAIDs in patients too low to affect DC function. It is also possible 
that the effect of NSAIDs in these patients is overruled by the strong stimulatory 
effect of imiquimod on NF-κB. After binding on TLR 7 or 8 on the surface of the DC, 
imiquimod induces activation of NF-κB, which results in a profound cellular immune 
response.8,9  
In conclusion, our data indicate that NSAIDs do not interfere with imiquimod 
immunomodifying activities and therefore can safely be used to reduce the symptoms 
of imiquimod side effects in uVIN patients during treatment. Furthermore, elevated 
CD1a+ and CD207+ cell counts in frequent NSAID-users seem to predict a good 
clinical response to imiquimod treatment.
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aBstract 
vulvar lichen sclerosus and lichen planus are t-cell mediated chronic skin 
disorders. although autoimmunity has been suggested, the exact pathogenesis 
of these disorders is still unknown.
therefore, the aim of the current study was to investigate the molecular 
and immunological mechanisms critical in the pathogenesis of vulvar lichen 
sclerosus and lichen planus. By using gene expression profiling and real-time 
rt-pcr experiments, we demonstrated a significantly increased expression of 
the pro-inflammatory cytokines (IFNγ, CXCR3, CXCL9, CXCL10, CXCL11, CCR5, 
CCL4, CCL5) specific for a th1 Ifnγ induced immune response. In addition, BIC/
microrna-155 (mir-155) – a microrna involved in regulation of the immune 
response – was significantly upregulated in lichen sclerosus and lichen planus 
(9.5- and 17.7- fold change respectively). Immunohistochemistry showed 
a significant t cell response, with pronounced dermal infiltrates of cd4+, 
cd8+ and foXp3+ cells. In conclusion, these data demonstrate an autoimmune 
phenotype in vulvar lichen sclerosus and lichen planus, characterized by 
increased levels of th1 specific cytokines, a dense t cell infiltrate and enhanced 
BIC/mir-155 expression. 
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IntroductIon
Vulvar lichen sclerosus (LS) and lichen planus (LP) are both chronic inflammatory skin 
disorders that have a negative impact on quality of life and may proceed to malignant 
disease.1 
LS can affect any part of the skin, but is most frequently seen in the anogenital 
area. Although it can occur at all ages, even among children, LS is most common 
in the fifth to sixth decade.2,3 Women with vulvar LS often present with severe 
pruritus and soreness of the vulvar and perianal area.2-4 Typically, lesions appear as 
a figure-of-eight pattern around the vulva and anus, with white atrophic lesions 
or hyperkeratosis. In advanced stages, there is destruction of the vulvar anatomy, 
characterized by resorption of the labia minora, narrowing of the introitus and 
a buried clitoris.3 
LP also generally develops in the fifth to sixth decade.5,6 In contrast to LS, the 
mucosa can be involved in LP, resulting in vaginal and oral lesions.7,8 Patients usually 
present with vulvar soreness, pruritus, burning, dyspareunia, and/or vaginal discharge. 
Erosive lesions, with denuded epithelium associated with typical white Wickham’s 
striae, can arise at the vulvar or vaginal mucosa, and alterations of normal vulvar 
architecture may occur. In severe cases, adhesions and stenosis can lead to complete 
obliteration of the vagina.5-7  
Histologically, both disorders are characterized by a band-like lymphocytic infiltrate 
and a thinned epidermis with vacuolar changes in the basal layer. In long standing, 
classic LS the lymphocytic infiltrate is located under a band of homogenized collagen 
below the dermoepidermal junction, while in LP this infiltrate is situated directly 
beneath the epidermis.1 However, histological evaluation of LS and LP can be difficult, 
because especially the first phase of LS can show histological overlap with LP.9
Local application of ultrapotent corticosteroids is still the treatment of choice 
for both disorders. If corticosteroids are not helpful in patients with LP, the use of 
topical calcineurin inhibitors (tacrolimus or pimecrolimus) may be considered.10 
However, all these treatment options only reduce symptoms and generally does 
not stop progression.1 This illustrates the importance of new treatment strategies. 
One example of such a new treatment option is photodynamic therapy (PDT). 
The possible antisclerotic and anti-inflammatory effect of PDT might be induced by 
the reduction of TGF-β1 and/or the increase of IL-10 after PDT.11 Since progression 
to vulvar squamous cell carcinoma has been reported for LS as well as LP, life-long 
follow-up of these patients is indicated.1 
The etiology of these disorders has not yet been elucidated. Various studies have 
suggested different etiological factors. Cases of familial LS and LP have been reported 
and an association with HLA class II antigens has been found, suggesting a genetic 
background.12-14 Other studies have suggested a role for local factors and infectious 
agents, such as an infection with Borrelia burgdorferi, human papillomavirus (HPV) 
or hepatitis C virus. However, the results of these studies are inconclusive and none 
of these agents has been proven to be pathogenetic.15-17 Current opinion suggest 
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an autoimmune pathogenesis for both disorders, since patients with LS and LP are 
more frequently diagnosed with autoimmune disorders such as vitiligo and thyroid 
disease, and the presence of autoantibodies, for example to extracellular matrix 
protein 1 (ECM1) in patients with LS, has been observed.18,19 
In summary, since it is not clear what causes LS or LP, the aim of this study was to 
elucidate the molecular mechanisms involved in the pathogenesis of vulvar LS and LP.
materIals & methods
patient samples
Fresh frozen and formalin-fixed tissues of patients with a clinically and histologically 
confirmed diagnosis of LS and LP were selected from the anonymous pathology 
archive of the Erasmus University Medical Center. Control samples were obtained 
from healthy women who underwent elective vulvar surgery for cosmetic reasons. 
Fresh tissues were directly frozen in liquid nitrogen after collection and were 
stored at -80ºC until further analysis. Cryosections of 10 µm were obtained and 
the first and tenth section in a series of 10 was stained to assess tissue morphology. 
The remaining sections were used to isolate total RNA using Trizol (Invitrogen, Life 
Technologies, Philadelphia, PA, USA) and quality and quantity was assessed on the 
Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA, USA). 
RNA was isolated from 14 control samples, 12 LS and 11 LP samples. From these 
samples, we selected 14 control, 8 LS and 5 LP samples for the microarray experiment. 
To confirm microarray data, we performed RT-PCR experiments using RNA of 4 LS and 
2 LP of the microarray samples, combined with RNA of other samples (4 LS and 6 LP). 
For immunohistochemistry we selected cryo- and paraffin sections of LS (n=16), 
LP (n=9) and control samples (n=10). Once more, to confirm microarray data, these 
samples were others than used for the microarray experiments.
The medical ethical committee of the Erasmus University Medical Center approved 
our study design and the protocol was compliant with the Helsinki Guidelines. 
microarray and microarray data analysis
Affymetrix U133plus2 GeneChips were used to obtain gene expression profiles of 8 
LS (median age 58 years, range 22–76), 5 LP (median age 59 years, range 51–78) and 
14 control samples (median age 40 years, range 17–54). In addition, nine samples of 
patients with usual type vulvar intraepithelial neoplasia (uVIN) (median age 39, range 
33–48), a vulvar disease with a strong lymphocytic dermal infiltrate, were used for 
the analysis of BIC/miR-155 gene expression. Isolation of RNA, staining, washing and 
scanning procedures were performed as described by the manufacturer (Affymetrix, 
Santa Clara, CA, USA).61 Raw (.CEL files) and normalized microarray data have been 
deposited in the GEO repository at NCBI under accession number GSE5563.
Differentially expressed genes were identified by using statistical analysis 
of microarrays (SAM). A False Discovery Rate (FDR) less than 1% was considered 
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statistically significant. Using OmniViz software hierarchical clustering of differentially 
expressed genes was performed.
Ontological analysis, using Ingenuity Pathway software (Ingenuity® Systems, 
www.ingenuity.com), was employed to assess the functional relevance of the 
observed differences in gene expression profiles.
Quantitative real-time rt-pcr
IFNγ,	IL17A,	IL17F,	IL22RA1	and	CXCL10. Validation of the expression of these genes	
was performed in 8 LS (of whom 4 were also used for microarray), 8 LP (of whom 
2 were used for microarray) and 8 control samples in duplicate using real-time 
quantitative RT-PCR (38 cycles, 15 sec at 95ºC, 30 sec at 59-62ºC and 1 min at 
72ºC) using the Opticon I (Applied Biosystems, Foster City, CA, USA) and SYBR Green 
ITM (Applied Biosystems). cDNA samples (10 ng each) were amplified with gene 
specific primer pairs (0.5 μM) in a total volume of 25 μl including 12.5 μl SYBR 
Green PCR master mix (Applied Biosystems). The housekeeping gene β-actin was 
used for normalization and all used PCR primers were intron spanning. The used 
primer sequences were as follows.
 
β-actin: 5’-TCCCTGGAGAAGAGCTACGA-3’(forward); 
 5’-AGGAAGGAAGGCTGGAAGAG-3’ (reverse). 
IFNγ: 5’-TGACCAGAGCATCCAAAAGA-3’(forward); 
 5’-CATGTATTGCTTTGCGTTGG-3’ (reverse). 
IL17A: 5’-ACCAATCCCAAAAGGTCCTC-3’(forward);
  5’-GGGGACAGAGTTCATGTGGT-3’(reverse). 
IL17F: 5’CCTCCCCCTGGAATTACACT-3’(forward); 
 5’-TTCCTTGAGCATTGATGCAG-3’(reverse). 
IL22RA1: 5’ACCCCAGACACGGTCTACAG-3’(forward);
  5’-GTAGAGCTCCGTGAGGTTGC-3’(reverse). 
CXCL10:  5’-CCACGTGTTGAGATCATTGC-3’(forward);
 5’-TTCTTGATGGCCTTCGATTC-3’(reverse).
The relative fold increase of real-time RT-PCR results was determined by the 2-∆∆Ct 
method62 using the average expression of the housekeeping gene (β-actin) as a control. 
MicroRNA-155	 (miR-155). Validation of the expression of miR-155 was 
performed using a two-step TaqMan RT-PCR assay (Applied Biosystems) according to 
manufacturers’ protocols in 5 LS, 5 LP and 5 control samples. The TaqMan® MicroRNA 
Reverse Transcription Kit (Applied Biosystems) was used for the preparation of cDNA; 
10 ng of total RNA was used per 15 μl RT reaction. Reverse transcription was performed 
in a PTC-200 Peltier Thermal Cycler (MJ Research, Biozym, Landgraaf, Belgium) for 30 
min at 16°C, 30 min at 42°C, 5 min at 85°C, and then held at 4°C. The RT products 
were subsequently amplified with sequence-specific human miRNA primers using the 
Applied Biosystems 7900HT Real-Time PCR system. The reactions were incubated in 
duplicate in a 96-well plate at 95°C for 10 min followed by 40 cycles at 95°C for 15 
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sec and at 60°C for 1 min. Amplification signals were computed with the SDS v.2.3 
software (Applied Biosystems). The relative fold increase of miR-155 to control was 
determined by the 2-∆∆Ct method62 using the average expression of two endogenous 
controls, RNU44 and RNU48. 
Immunohistochemistry 
Immunohistochemical staining was performed on 6 μm thick frozen tissue sections. 
The following markers were used: CD4, marker for T helper cells (MT.310; Dako, 
Glostrup, Denmark); CD8, marker for cytotoxic T cells (DK25; Dako); FOXP3, marker 
for regulatory T cells (Treg) (EBioscience Ltd., Hatfield, UK) and CD19, marker for B 
cells (Beckmann Coulter, Brea, USA), in dilutions of respectively 1:50, 1:50, 1:50 and 
1:25. Staining was performed as described previously.63  
For identification of immature dendritic cells (DCs)/ Langerhans cells, staining for 
CD1a (clone O10, Immunotech, Marseille, France) in a dilution of 1:10 was performed 
on paraffin-embedded tissue sections as described earlier.55 
Stained cells were counted throughout the entire epidermal thickness and 100 
μm deep into the dermis in a blinded session. Because the cell infiltrate in LS tissue 
is localized in the mid-dermis below a subepidermal sclerotic zone, LS tissues were 
counted 100 μm deep into the mid-dermal infiltrate. After measuring the total area 
of the epidermis and dermis by using the Leica Image Analysis System, the number of 
cells per square millimeter was calculated for each layer separately.  
statistical analysis
Data analysis was performed with the use of the SPSS 17.0 software package for 
Windows. Immunohistochemistry and PCR data were analyzed using the non-parametric 
Kruskal-Wallis test and the Mann-Whitney test for independent samples. Correlation 
studies were performed with the non-parametric Spearman’s correlation coefficient. 
A two-tailed P-value of P<0.05 was chosen to represent statistical significance. 
results
Identification of differentially expressed genes in ls and lp
To study signaling pathways involved in both disorders, we performed gene expression 
arrays. Using SAM analysis we found 6643 differentially expressed probesets between 
LS and controls, 7354 between LP and controls and 623 between LS and LP (Fig. 1). 
The number of differentially expressed genes between LS and LP was only 10% of 
the number of genes differentially expressed between LP and controls, or between LS 
and controls (the complete list of differentially expressed genes can be obtained from 
supplementary Table 1, http://www.erasmusmc.nl/47393/1584119/1603959/Terlou).
By using Ingenuity Pathway Analysis we identified biological functions that were 
significantly regulated in LS and LP as compared to control samples. The following 
biological functions were found (P<0.001): 1) Antigen presentation, 2) Cell-mediated 
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immune response, 3) Humoral immune response and 4) Inflammatory response 
(supplementary Fig. 1, http://www.erasmusmc.nl/47393/1584119/1603959/Terlou). 
High regulation of these biological functions is caused by the fact that most differentially 
expressed genes between LS/LP and control tissues are involved in pathways related to 
the immune response. This result was also found by Edmonds et al., who studied gene 
expression profiling in male genital lichen sclerosus.20 
In order to investigate the immune response in more detail, we used the KEGG 
cytokine-cytokine receptor pathway (www.genome.jp/kegg/) as a background for 
our own immune signaling data. Many cytokines were upregulated in LS and LP 
(Fig. 2). For most genes this upregulation was more pronounced in LP than in LS. By 
LP LS control
LS versus control
6643 genes
LP versus control
7354 genes
LP versus LS
623 genes
A
B
C 
Figure 1. 
LP LS control
LS versus control
6643 genes
LP versus control
7354 genes
LP versus LS
623 genes
A
B
C 
Figure 1. 
Figure 1. Gene expression profiles of lichen sclerosus (LS) and lichen planus (LP). Unsupervised clus-
tering of expression profiles from 18 control, 5 LP and 10 LS samples. A. 6643 genes were differen-
tially regulated in LS versus control. B. 7354 genes were differentially regulated in LP versus control. 
C. 623 genes were differentially regulated in LP versus LS. Each row represents one gene (red: upregu-
lated, blue: downregulated), each column one expression profile from one tissue sample.
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studying those cytokines in more detail, we focused on well-known pro-inflammatory 
and anti-inflammatory cytokines.21 Of the pro-inflammatory cytokines we found 
upregulation of IL1, IL6 (only in LP), IL7, IL15, IFNγ and TNFα. For most of the anti-
inflammatory cytokines no modulation was found (for example for IL4 and IL13), and 
only slight upregulation of TGFβ1 (only in LP) and TGFβ2 (only in LS). Interestingly 
IL11, also known as an anti-inflammatory cytokine, was downregulated in LS and 
LP. In summary, significantly more pro-inflammatory cytokines were highly expressed 
in LS and LP, which is regarded as an indication for a cellular T helper type 1 (Th1) 
response.22 
IFNγ is one of the key players in the Th1 response and its mRNA was strongly 
upregulated in LS and LP (3.5- and 7.8-fold, respectively, Fig. 2). It is produced by T 
helper cells (CD4+ T cells), which are characterized by chemokine-receptors CXCR3 
and CCR5.23 As shown later (Fig. 4), in the dermis significantly higher levels of CD4+ 
T cells were seen in LS and LP, and as expected both CXCR3 and CCR5 were highly 
expressed in both disorders. Besides this strong expression of CXCR3	and CCR5, their 
activating ligands CXCL9, CXCL10, CXCL11	and CCL3,	CCL4,	respectively, were also 
strongly upregulated. These results indicate that the infiltrate of CD4+ T cells seems 
to be involved in the production of significant amounts of IFNγ, CXCL9, CXCL10, 
CXCL11,	CCL3 and	CCL4,	thus further stimulating a cellular Th1 response in LS and 
LP. Other stimulatory factors for production of Th1 cytokines and consequently for 
the differentiation of T cells to the Th1 phenotype, are cytokines of the IL-1 family, 
namely interleukin-1 alpha (IL1α), interleukin-1 beta (IL1β) and interleukin-18 (IL18) 
(Fig. 2, IL-1 family is indicated with a black box). We found upregulation of IL1α 
and the IL18 receptor in LS and LP and upregulation of IL1β in LP. To activate these 
inflammatory cytokines, caspase 1 is necessary. As expected, caspase 1 (CASP1) was 
significantly upregulated in LS (1.8-fold) as well as in LP (2.0-fold).  
All the observations described above suggest a strong Th1 response. However, to 
investigate the potential role of Th2 and Th17 next to Th1, we performed real-time 
RT-PCR on important regulators of these responses. A clear and pronounced 
upregulation of IFNγ and CXCL10 was confirmed, indicating a Th1 response, while 
we found no significant regulation of key players in the Th2 (CCR3, IL4) and Th17 
(IL17A, IL17F, IL22R) response (Fig.3A).
One other important finding concerning the immune response was the strong 
upregulation of BIC, a gene which encodes for microRNA-155 (miR-155). MiR-155 
plays an important role in regulating homeostasis of the immune system. It 
regulates production of cytokines, chemokines and transcription factors, but has 
also been shown to promote T cell-dependent autoimmune inflammation.24,25 
We found strong upregulation of	BIC/miR-155 in LS (9.5-fold) and LP (17.7-fold) 
compared to controls (Fig. 3B). This upregulation was confirmed by TaqMan RT-PCR 
(LS: 8,5-fold and LP:17.5-fold, Fig. 3A). In contrast, no differential gene expression 
of BIC/miR-155 was observed between controls and uVIN samples, a vulvar disease 
with a strong lymphocytic dermal infiltrate (Fig. 3B).   
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Immune cell counts in ls and lp
In order to document the composition of the cellular infiltrate, presence of CD4+ 
T cells, CD8+ T cells, FOXP3+ Treg cells, CD1a+ DCs/Langerhans cells and CD19+ B 
cells was assessed. In LS no differences in immune cell counts were observed in 
the epidermis compared to controls. However, in the dermis, cell counts for CD8+ 
T cells and FOXP3+ Treg cells were significantly higher than in controls (P<0.001 and 
P=0.013 respectively, Fig. 4 and supplementary Table 2, http://www.erasmusmc.
nl/47393/1584119/1603959/Terlou). In contrast, CD1a+ cells were significantly 
decreased in the dermis (P=0.008, supplementary Table 2).
In the epidermis of LP, FOXP3+ Treg cells were significantly increased compared to 
controls (P=0.024), and no differences were observed for the other immune cells. In 
the dermis, however, a significant increase in CD4+ T cells, CD8+ T cells, FOXP3+ Treg 
cells and CD19+ B cells was observed in LP in comparison with controls (Fig. 4 and 
supplementary Table 2). Similar to differences in gene expression levels, differences in 
immune cell counts were more pronounced in LP than in LS. 
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Figure 3. Real-time RT-PCR results. A. Differences in gene expression are visualized for key players 
in the Th1, Th2 and Th17 response and validation of miR-155 expression by TaqMan RT-PCR (control 
n=5, lichen sclerosus (LS) n=5 and lichen planus (LP) n=5). 1 No significant difference on microarray 
data and therefore no real-time RT-PCR was performed. B. Gene expression of BIC/miR-155 in con-
trols (n=14), LS (n=8), LP (n=5) and usual type vulvar intraepithelial neoplasia (uVIN) (n=9). 
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dIscussIon
Recent publications indicate that LS and LP may be autoimmune disorders. Firstly, 
like autoimmune diseases, genital LS and LP are more common in women than in 
men.3,26 Secondly, patients with LS and LP are more frequently diagnosed with other 
autoimmune disorders such as vitiligo and thyroid disease, and patients with LP show 
more frequently circulating autoantibodies.18 Also, the presence of autoreactive T 
cells against basement membrane zone components has been observed in LS and 
LP.19,27-29 Lastly, an association of LS with HLA class II antigen DQ7 and of LP with HLA 
DRB1*0201 has been demonstrated.12-14
From the above, it is hypothesized that aberrant immune signaling plays a role in 
the pathogenesis of LS and LP, although the exact molecular mechanisms which lead 
to these immunological changes have not yet been clarified. Here we will discuss our 
main findings which further corroborate that autoinflammatory mechanisms are the 
basis of both LS and LP.
ls and lp are characterized by a strong th1 response 
In both disorders, the lymphocytic infiltrate contained primarily T cells. In LS patients, 
a significant increase in CD8+ T cells and Treg cells was observed, while CD4+ T cell 
counts in LS were not significantly increased (P=0.07). For LP, a more pronounced 
increase for all immune cell counts was observed, with significantly increased T- and 
B cell counts. These data are in agreement with published investigations describing 
dense T cell infiltrates in LS and LP.30-33 
To investigate whether these T cells are involved in a Th1 or Th2 response, 
we studied the different chemokine receptors. Th1 cells are characterized by the 
expression of CXCR3 and CCR5, while Th2 cells express CCR3 and CCR4.23 We found 
high levels of CXCR3 and CCR5 in LS and LP and no expression of CCR3 and CCR4, 
indicating an infiltrate of Th1 cells. Although the role of Th1 response in autoimmune 
disorders is not completely understood, it seems to play an important role in the 
induction, maintenance and exacerbation of chronic inflammation. This inflammation 
is controlled by the presence of Th1 cells, which produce IFNγ. High levels of IFNγ 
will attract and stimulate different immune and epithelial cells. In reaction to this, 
these cells will produce ligands for the CXCR3 and CCR5 receptors, namely cytokines 
CXCL9, CXCL10, CXCL11, CCL3 and CCL4 (Fig. 2), thereby attracting more Th1 
cells to the site of inflammation. As a result the Th1 response will be maintained 
and intensified, resulting in chronic inflammation.34 The important role for the Th1 
phenotype in LS and LP was further illustrated by the upregulation of IL1α and 
CASP1. The binding of CASP1 to cytokines of the IL-1 family results in activation of 
the inflammatory processes and suggest the involvement of inflammasomes. 
 The role of the above described cytokines in relation to autoimmunity has 
previously been investigated and reviewed.34-36 In various autoinflammatory and 
autoimmune disorders, like multiple sclerosis,37-39 rheumatoid arthritis,40 systemic 
lupus erythematosus (SLE),41 Graves’ disease,42,43 type 1 diabetes mellitus44 and 
125
7
A
U
TO
IM
M
U
N
E PH
EN
O
TY
PE IN
 V
U
LVA
R LS A
N
D
 LP
Figure 5. 
Figure 5. Hypothesized mechanism of pathogenesis of lichen sclerosus (LS) and lichen planus (LP). 
MiR-155 is strongly upregulated in LS and LP, and possibly affects Treg cell mediated suppression of 
CD4+ T cells by affecting the suppressive function of Treg cells and by reducing the susceptibility of 
CD4+ T cells for Treg cell mediated suppression. The T cell response is skewed to Th1. Upregulation 
of CXCR3 and CCR5 (Th1 receptors) results in increased production of IFNγ, which attracts differ-
ent dendritic, epithelial and endothelial cells. In response, these cells will produce high amounts of 
CXCL9, CXCL10, CXCL11, and CCL3, CCL4 which in turn intensify and maintain the Th 1 response. 
Correlations between IFNγ and these ligands are shown on the right (Spearman’s correlation coeffi-
cient). Blue: controls (n=18); red: LS (n=10); orange: LP (n=5).
table 1. expression of cytokines and mir-155 in different autoinflammatory/autoimmune 
disorders according to literature.
disorder cytokine profile
Multiple Sclerosis37-39,58 CXCR3↑, CXCL9↑, CXCL10↑, IFNγ↑, miR-155↑
Rheumatoid arthritis40,56,59 CXCR3↑, CXCL9↑, CXCL10↑, IFNγ↑, miR-155↑
Systemic Lupus Erythematosus41,57 CXCR3↑, CXCL9↑, CXCL10↑, IFNγ↑, miR-155↑
Graves’ disease42,43 CXCR3↑, CXCL9↑, CXCL10↑, IFNγ↑
Type 1 diabetes mellitus44 CXCR3↑, CXCL9↑, CXCL10↑, IFNγ↑
Vitiligo45 CXCR3↑, IFNγ↑
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vitiligo,45 high levels of CXCR3 and its ligands are described (Table 1). In Figure 5 
a schematic representation of this feed-forward autoinflammatory process is shown, 
which, according to our data, plays a major role in the autoinflammatory pathogenesis 
of LS and LP. Furthermore, the upregulation of CASP1 and IL1α, also suggests a role 
for inflammosome activity in both disorders, as previously has been described for 
various autoimmune diseases.46 Future investigations should focus on the role of 
inflammosomes in LS and LP.
Next to increased immune cell counts and expression of pro-inflammatory 
cytokines, we also observed an increased expression of miR-155. As indicated in Figure 
5, elevated expression of miR-155 may be a primary molecular event that initiates the 
activation of immune cells. This concept will be discussed in the next section.   
mir-155 is profoundly upregulated in ls and lp
MicroRNAs are small endogenous noncoding RNAs that post-transcriptionally 
regulate gene expression by base-pairing to imperfect complementary target sites 
on the RNA, or by partially blocking translation.47,48 It is known that miR-155 plays a 
critical role in regulating homeostasis of the immune system. It regulates production 
of cytokines, chemokines and transcription factors, and is induced by endotoxins via 
toll-like receptor signaling.24,49-51 Furthermore, miR-155 is expressed in several types 
of activated immune cells, such as macrophages, DCs, B and T cells, and promotes T 
cell differentiation towards Th1.24,49,52-54 
Based on this, it can be hypothesized that increased expression of miR-155 in LS 
and LP originates from the dense T cell infiltrate in both disorders. However, we did 
not observe overexpression of BIC/miR-155 in uVIN, a vulvar disease with also a strong 
dermal lymphocytic infiltrate (Fig. 3B). A possible explanation for the difference in 
expression of miR-155 in LS/LP and in uVIN could be that the lymphocytic infiltrate 
in LS and LP primarily consists of activated	T cells, while in uVIN the T cell response 
seems to be ineffective since these T cells are unable to clear HPV, the underlying 
cause of uVIN.55 
A role for miR-155 in autoimmune diseases has been demonstrated recently, and 
increased expression was observed in different autoinflammatory and autoimmune 
diseases, such as multiple sclerosis and rheumatoid arthritis (Table 1).25,56-59 One 
important mechanism inducing autoimmunity is loss of immune tolerance. Normally, 
unwanted immune responses are controlled by the suppressive function of Treg cells, 
which are known to play a critical role in maintenance of immune tolerance. In a mouse 
model studying SLE, it was observed that artificially enhanced miR-155 expression 
resulted in an altered Treg cell phenotype and thereby in a reduced suppressive 
function of Treg cells (despite an increase in Treg cell counts).57 In addition, another 
study showed that increased miR-155 levels in CD4+ T cells resulted in reduced Treg 
cell mediated suppression.60 For LS and LP a similar mechanism may be at work: 
because of enhanced miR-155 levels the observed increased numbers of Treg cells 
may not fully affect CD4+ T cells thus resulting in impaired immune tolerance towards 
self-antigens causing autoimmunity.
127
7
A
U
TO
IM
M
U
N
E PH
EN
O
TY
PE IN
 V
U
LVA
R LS A
N
D
 LP
ls and lp have profound characteristics of an autoimmune disorder
Summarizing our data, we demonstrate high levels of BIC/miR-155 and increased 
gene expression of pro-inflammatory cytokines involved in autoimmunity, with an 
important role for CXCR3 and CCR5 and their ligands resulting in a dense infiltration 
of T cells. Overall, these observations were more pronounced in LP than in LS. In 
addition, Cooper et al. found recently significant higher levels of auto-antibodies 
in 52/126 (41%) women with LP and 39/190 (21%) women with LS compared to 
controls.18 We also found autoantibodies in a high percentage of patients with LP 
(32%) and LS (14%) (data not shown). Taken together with previous data about 
associations with HLA-DR, other autoimmune diseases and demonstration of 
autoreactive T cells, an autoimmunological basis for LS and LP seems likely. Future 
studies should focus on the role of miR-155 and the immune response in these 
disorders, which may be a focus for more targeted therapies.
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general dIscussIon
Vulvar and vaginal premalignant epithelial disorders are a burden for the patient, with 
severe and long-lasting symptoms and a clear psychosexual impact. Although the 
awareness for these disorders seems to be increased over the last years, reflected by 
more specialized vulvar clinics and a search for new treatment modalities, unresolved 
questions about the exact pathogenesis of these diseases remain and better treatment 
options are still very much needed.
treatment of usual type vIn with imiquimod
Vulvar intraepithelial neoplasia (VIN) is one of the vulvar disorders with a premalignant 
potential.1,2 The incidence of usual type VIN (uVIN), which is caused by a persistent 
infection with high-risk type human papillomavirus (HPV), has increased especially in 
younger women.3,4 Because treatment options like surgery and laser vaporization are 
mutilating, a trend towards less invasive treatments that preserve anatomy and sexual 
function has been observed in recent years. Topical treatment is attractive because it 
can be applied directly by the patient and is easily monitored for efficacy. Furthermore, 
new treatment modalities for uVIN aiming to enhance patients’ immune response and 
thereby clear the persistent high risk type HPV infection, are of interest. The rationale 
behind such treatment modalities is that the immune response in uVIN lesions seems 
to be ineffective, since uVIN lesions are characterized by an immunosuppressive state 
in the epidermis, while an insufficient immune response to HPV occurs in the dermis 
of uVIN.5-8 In addition, it has been demonstrated that patients with persistent disease 
show no detectable anti-HPV T-cell responses.9 
Several studies demonstrated that the immune response modifier imiquimod, 
which is applied as imiquimod 5% cream, is a promising therapy for uVIN.10,11 Our 
group performed a double-blinded, placebo-controlled randomized clinical trial 
(RCT) and demonstrated a complete response after 16 weeks of treatment in 35% 
of patients and a reduction in lesion size of at least 25% in an additional 46% 
of patients. More importantly, HPV was cleared in 58% of patients, suggesting an 
adequate clearance of the underlying cause of uVIN.11 From these results, it was 
concluded that imiquimod should be the first-line treatment option for uVIN. However, 
until now long-term follow-up data on imiquimod as a treatment for uVIN were not 
available. In this thesis it was demonstrated that the recurrence rate in complete 
responders after imiquimod treatment is relatively low compared to other treatments 
such as local excision, laser vaporization or photodynamic therapy (PDT), which have 
recurrence rates of respectively 15-50%, 23-40% and 48%.2,12-14 In our study, 8 
of 9 complete responders (89%) were still disease-free after imiquimod treatment 
with a median follow-up of 7.3 years. Two additional patients with an initial partial 
response became complete responder after a prolonged treatment with imiquimod 
and were also still disease-free at long-term (>5 years) follow-up.15 From these data 
we conclude that in case of a complete response, imiquimod is an effective treatment 
in the long-term. However, these recurrence rates are based on a small number of 
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patients, and the study described in this thesis is the only one reporting on long-term 
clinical response after imiquimod treatment so far.
other therapeutic approaches for usual type vIn
Although imiquimod is an effective treatment in a number of uVIN patients, there is 
still a significant group of patients that do not respond or have only a partial response 
upon imiquimod treatment. In case of a partial response, imiquimod is effective to 
reduce lesion size and could therefore be used preceding surgery, thereby limiting the 
mutilating effects of surgery. However, in these partial responders high recurrence 
rates are still a problem, since we observed that most partial and non-responders 
who were secondary treated with surgery for their residual lesions suffered from 
recurrences.15 Therefore, treating these patients is a challenge and accordingly other 
approaches are needed to improve the response rates in these patients. 
Longer	 treatment. A straightforward approach is to prolong the treatment 
period of imiquimod. We observed that small lesions are more likely to respond to 
imiquimod treatment, and two patients with a partial response during the initial 
RCT became complete responder after a prolonged treatment with imiquimod.15 In 
case of side effects as local inflammation, burning or flu-like symptoms, patients 
can use nonsteroidal anti-inflammatory drugs (NSAIDs) or paracetamol to reduce 
these side effects without interfering with imiquimods immunomodifying activities, 
as we demonstrated in chapter 5.16 This might increase patients’ compliance to 
treatment, in particular when longer treatment periods are needed. For these reasons 
we consider prolonged treatment with imiquimod a feasible addition to the current 
16-week period of treatment.
Therapeutic	vaccination. Another way to modulate the local immune response in 
favor of clearance of a persistent HPV infection is boosting the local immune response 
by therapeutic vaccination. A recent study17 reported on 20 women with HPV-16-
positive uVIN that were vaccinated three or four times with a mix of long peptides 
from the HPV 16 viral oncoproteins E6 and E7. Three months after vaccination, 5 of 
20 patients had a complete response, increasing to 9 of 19 (47%) at 12 months after 
last vaccination. A partial response was observed in seven patients after 3 months 
and in six after 12 months follow-up. Complete response rate was maintained at 24 
months of follow-up. Interestingly, the authors also found that complete response 
was associated with lesion size. Patients with smaller lesions had a significantly 
stronger HPV-specific T-cell response with higher IFNγ than patients with large lesions, 
indicating that the vaccine-induced HPV16-specific T-cell response is regulated 
differently in patients with larger lesions.18 Summarizing these data, therapeutic 
vaccination can lead to a complete response in uVIN patients by inducing HPV-16 
specific immunity. However, similar to treatment with imiquimod, still a number of 
patients do not or only partially respond. 
Combination	therapy. Since it has been demonstrated that HPV-16-positive VIN 
patients with a pre-existing HPV-specific type 1 T-cell response are more likely to 
have a strong response to imiquimod treatment,19 another treatment strategy could 
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be to combine imiquimod with HPV vaccination, which has been investigated in one 
study.20 In this study, 19 VIN patients were treated with imiquimod on the vulva 
for 8 weeks followed by three doses of therapeutic HPV vaccination, and complete 
histologic regression was observed in 32% of women at week 10, increasing to 58% 
at week 20 and 63% at week 52.20 These results are promising, but data on long-term 
follow-up are still needed. Moreover, starting with HPV vaccination followed by 
imiquimod treatment could improve response to treatment. With such a treatment 
protocol, an HPV-specific type 1 T-cell response is induced before start of imiquimod 
treatment. Because a preexisting HPV-specific type 1 T-cell response is associated 
with a favorable clinical outcome upon imiquimod treatment,19 this might result in 
a complete response in more patients.
Lifestyle	change. Finally, it is of interest to investigate the impact of smoking on 
response to immunomodifying therapies in uVIN patients. It is known that smoking 
is an important risk factor for uVIN,21 which is reflected by the significant number of 
smokers in the above mentioned studies (i.e. 23/26 of imiquimod treated patients 
smoked in the RCT performed by our group11 and 15/19 patients smoked in the study 
from Daayana et	al.20). Smoking increases nitric oxide levels in tissues and it is known 
that high nitric oxide levels in cells infected with high-risk type HPV result in decreased 
levels of the tumor suppressor genes p53 and pRb, thus negatively affecting DNA 
integrity and bypassing successful immunoclearance of the disease.22 In our pilot 
study investigating the efficacy of imiquimod as a treatment for vaginal intraepithelial 
neoplasia (VAIN), a negative correlation between smoking and histologic response 
to imiquimod treatment was observed (chapter 6). This diminished response to 
imiquimod might be due to an already impaired local immune response in smokers. 
Hence, smokers should be encouraged to stop smoking in particular before start of 
immunomodifying treatments.
future perspectives on treatment of hpv-related vulvar and vaginal 
disorders
Recently, prophylactic HPV vaccination was implemented in the general population 
in most European countries for the prevention of HPV-related premalignant and 
malignant diseases.23 For that reason, the incidence and as a consequence the 
impact of HPV-related diseases will probably diminish in the future. However, since 
prophylactic vaccination is only directed to high-risk type HPV 16 and 18, premalignant 
diseases caused by other high-risk HPV types still need treatment. Moreover, it will 
take several decades until prophylactic vaccination reduces the incidence of HPV-
related diseases in the general population.24 In the mean time, effective treatment is 
needed. Combination of different treatment strategies as imiquimod and therapeutic 
vaccination might increase response rate in patients with uVIN.
In addition, immunomodifying treatments could also be useful for other HPV-
related disorders of the anogenital tract, such as VAIN and cervical intraepithelial 
neoplasia (CIN). Although VAIN is relatively rare, its treatment is difficult with high 
recurrence rates and considerable morbidity. Given that treatments as vaginectomy 
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can impair sexual function, application of imiquimod could be a promising alternative 
treatment. We demonstrated a complete histologic response after imiquimod 
treatment in 3/9 (33%) of VAIN patients and a partial response was observed in 
three patients. Although the sample size is small, these results are promising and 
need further investigation in larger studies. Furthermore, response rates should be 
compared with other treatment options as laser vaporization.
Finally, immunotherapy as a treatment for cancer has been tested extensively in 
the past few years. Immunotherapies such as cytokines or dendritic cell vaccines 
induce a Th1 immune response and activate cytotoxic T-lymphocytes to eliminate the 
tumor.25,26 In case VIN has already progressed to invasive cancer, there might also be 
a role for such immunotherapies in the treatment of vulvar squamous cell carcinoma.
non-hpv related vulvar disorders: immunity in lichen sclerosus and 
lichen planus
Like HPV-related vulvar disorders, lichen sclerosus (LS) and lichen planus (LP) seem to 
be diagnosed more frequently, probably due to an increased awareness by patients 
and specialists. Although evidence exist that both disorders are chronic autoimmune 
mediated diseases, the exact pathogenesis of LS and LP is still unclear.27,28 Furthermore, 
both disorders are difficult to treat. Topical ultrapotent corticosteroids are currently 
the treatment of choice for LS and LP.27,29 However, treatment only reduces symptoms 
and side effects as dermal atrophy make long-term treatment often complicated. 
To develop more curative therapies, more knowledge is needed about the exact 
pathogenesis of LS and LP. For that reason, the molecular and immunological 
mechanisms critical in the pathogenesis of LS and LP were investigated in this thesis 
(chapter 7). We observed an autoimmune phenotype in both diseases, with a strong 
Th1 response illustrated by a dense T-cell infiltrate and high levels of Th1 specific 
cytokines. 
Another important finding was the overexpression of microRNA-155 (miR-155). 
The role of microRNAs (miRNAs) - which act as post-transcriptional gene regulators - 
was unknown until recently. Over the last decade, more and more studies have found 
that miRNA regulatory pathways are important in the pathogenesis of various diseases 
and altered expression of miRNAs has been demonstrated in cancers, autoimmune 
diseases, but also inflammatory skin conditions.30-32 MiR-155 is a miRNA that plays 
a role in regulating homeostasis of the immune system, as it regulates production 
of cytokines, chemokines and transcription factors and is induced by endotoxins via 
toll-like receptor signaling.33,34 In addition, miR-155 shows increased expression in 
activated immune cells and has proven to be involved in autoimmunity.35-37 It plays 
an important role in driving chronic inflammation that is inappropriately directed at 
tissue-specific antigens,35 and high levels of miR-155 have been observed in different 
autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis.38,39 
Although we demonstrate increased expression of miR-155 in LS and LP, which could 
be an important step in pathogenesis, the potential role of miR-155 in these disorders 
is still unclear. To explore the role of miR-155, it is important to identify the cells that 
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express miR-155 and investigate which genes are targeted by miR-155 in LS and LP. 
Also, miRNA profiling studies are necessary to further identify and characterize other 
disease-specific miRNAs. 
future perspectives on treatment of vulvar ls and lp
We demonstrated an autoimmune phenotype in vulvar LS and LP, which is also 
supported by the finding of autoantibodies in a high percentage of patients, and 
by previous data about associations with HLA-DR, other autoimmune diseases 
and demonstration of autoreactive T cells.40,41 In the future, approaches targeting 
the immune response should be considered to find curative treatments. 
An interesting perspective for more targeted therapies could be the suppression of 
miR-155 by topical application of antimiRNA oligonucleotides (antagomirs). However, 
development of antimiRNA oligonucleotides that can bind strongly to the miRNA 
and are stable enough in physiological conditions remains a challenge.42 Moreover, 
the exact pathogenesis and role of miR-155 first need further clarification.
final remark
Treatment of vulvar and vaginal premalignant epithelial disorders is challenging. 
Although promising less invasive treatment options have been investigated over 
the past few years, no “gold-standard” treatments exist for these diseases. In 
addition, very long-term follow-up is required, since disease recurrence is common. 
Therefore, an individual treatment approach is essential.
Finally, since vulvar and vaginal epithelial disorders can have a negative impact on 
quality of life and on sexual functioning,43,44 it is important that clinicians pay attention 
to these psychosexual sequelae. The founding of patient support groups and the 
development of specialized vulvar clinics in which dermatologists, gynecologists and 
sexologists work together, are of great significance to improve individual patient care. 
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summary
Vulvar and vaginal premalignant disorders are a burden for the patient and have 
a high psychosexual impact. Women with vulvar premalignant lesions such as vulvar 
intraepithelial neoplasia (VIN), often have severe and long-lasting symptoms and 
treatment is complicated. In the past, surgery was the treatment of choice, but 
recurrence rates are high. In addition, surgical treatments can mutilate the vulva, 
causing psychosexual distress. As a consequence, several studies investigating 
less invasive treatment options that preserve anatomy were initiated over the last 
years. These new treatment modalities aim to modify patients’ immune response 
and thereby clear the initial cause of the disease: a persistent infection with human 
papillomavirus (HPV). Furthermore, topical treatments are attractive because they can 
be applied directly by the patient and are easily monitored for efficacy. 
The aim of this thesis was to investigate immune regulation of premalignant vulvar 
and vaginal disorders, and we focused in particular on the clinical and immunological 
effects of treatment with the immune response modifier imiquimod.
In Chapter 1 a general introduction is given about the vulva, the immune response 
and the premalignant vulvar disorders VIN, lichen	sclerosus	and lichen	planus.
An extensive overview of VIN, vulvar	 Paget’s	 disease and melanoma	 in	 situ, is 
given in Chapter 2. Of the premalignant vulvar disorders, VIN is diagnosed more and 
more frequently. In contrast, vulvar Paget’s disease and melanoma in situ are two rare 
diseases. Nevertheless, because of their malignant potential, a vulvar specialist should 
also be aware of these diagnoses and be familiar with the best way to manage these 
diseases.
Usual	 type VIN (uVIN) is caused by a persistent infection with HPV, and the 
lack of an appropriate immune response is of critical importance in the etiology of 
uVIN. Imiquimod is an immune response modifier that activates the cellular immune 
response. For that reason, it was previously tested as a treatment for uVIN. In a recent 
placebo-controlled, double-blinded randomized clinical trial (RCT) by our group (van 
Seters et	al.), it was observed that 35% of patients had a complete response after 
treatment with imiquimod and 46% a partial response. All complete responders 
remained disease-free at one year follow-up. However, long-term follow-up results 
after imiquimod treatment were still lacking. Therefore, as is described in Chapter 
3, we performed a study in which we assessed the long-term (>5 years) efficacy of 
imiquimod as a treatment for uVIN. Twenty-four of 26 patients who were treated 
with imiquimod during the initial RCT, were seen for follow-up. Median follow-up 
period was 7.2 years. uVIN recurred in one of nine complete responders. Of the initial 
partial responders, two became disease-free after additional imiquimod treatment. 
In the other partial responders, uVIN recurred at least once after the initial RCT. 
In long-term complete responders, lesion size at study entry was smaller and these 
patients had a significantly better global quality of life at follow-up than patients with 
residual disease and/or recurrence after imiquimod treatment. Our data indicate that 
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treatment with imiquimod is an effective long-term therapy for uVIN. Small lesions 
are more likely to respond completely to imiquimod treatment; therefore treatment 
period in the initial RCT might have been too short to be effective for larger lesions. 
Consequently we advise prolonging the treatment period until regression has stopped. 
Chapter 4 describes differences in immune cell levels and in the expression of 
p16INK4a, which is a specific marker for high-risk type HPV, in uVIN tissue before and 
after imiquimod treatment in relation to HPV clearance and clinical response. Immune 
cell counts and p16INK4a expression before and after imiquimod treatment were 
investigated in patients who cleared HPV and patients who did not clear HPV after 
treatment, and in healthy controls. Before imiquimod treatment, both HPV cleared 
and HPV non-cleared patients showed significantly upregulated immune cell counts 
compared to healthy controls. However, in patients that cleared HPV and showed 
histologic regression after imiquimod treatment, immune cell counts and p16INK4a 
expression were normalized to control levels. These data indicate that imiquimod-
induced clearance of HPV results in normalization of counts for certain immune cells 
and is strongly correlated with histologic regression of uVIN. 
Based on the previously shown efficacy of imiquimod as a treatment for uVIN, 
imiquimod is now considered first-line treatment for uVIN in the Netherlands. 
Treatment with imiquimod, however, is not always tolerated well. Patients using 
imiquimod frequently complain of side effects such as severe local inflammation, 
itching or burning, flulike symptoms, weariness and headache. We observed that 
patients treated with imiquimod commonly use nonsteroidal anti-inflammatory drugs 
(NSAIDs) or paracetamol in order to reduce these side effects. Since the effect of 
NSAIDs in patients using imiquimod is unknown, we describe in Chapter 5 whether 
NSAID-use, which has been documented to inhibit the cell-mediated immune 
response, interferes with the outcome of imiquimod treatment and thereby can 
interfere with imiquimods immunomodifying activities. We demonstrate in an in	vitro	
study about the effect of NSAIDs on dendritic cells (DCs) and Langerhans cells (LCs) 
that NSAIDs neither affect the ability of DCs and LCs to stimulate T-cell proliferation 
nor the production of cytokines (although an effect was observed on the expression 
of DC and LC maturation markers). In agreement with this, in uVIN patients treated 
with imiquimod, no interference of frequent NSAID-use with clinical outcome was 
observed. Our data indicate that NSAID-use does not seem to interfere with DC and 
LC function and does not interfere with immunomodulatory properties of imiquimod 
in uVIN patients. Therefore, NSAIDs can safely be used to reduce imiquimod side 
effects in uVIN patients during treatment.
Chapter 6 describes the efficacy and tolerability of imiquimod as a treatment 
for vaginal intraepithelial neoplasia (VAIN), which is also caused by a persistent HPV 
infection. In this pilot study, fourteen patients with histological confirmed VAIN 
were treated with imiquimod twice weekly for 16 weeks. Twelve of 14 patients 
completed treatment, while two patients stopped due to severe side effects. Three 
of nine patients (33%) from whom biopsies were available after treatment had 
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a complete histologic response, and three patients (33%) showed partial regression. 
In addition, one of three patients from whom only cytology was available, had 
a negative PAP-smear after treatment, and one showed a partial response. Furthermore, 
smoking was negatively correlated with histologic response to imiquimod. These 
preliminary data indicate that self-administration of imiquimod, which can be done 
easily by the patient at home and conserves anatomy and sexual function, can be 
an effective alternative treatment for VAIN in particular in patients with multifocal 
VAIN or contraindications for surgery. However, due to possible side effects, patients 
should be carefully instructed beforehand and followed during treatment.
In Chapter 7, the molecular and immunological mechanisms involved in vulvar 
lichen sclerosus and lichen planus were investigated in order to further clarify the 
pathogenesis of both diseases. By performing gene expression profiling and RT-PCR 
experiments, we demonstrated a significantly increased expression of pro-inflammatory 
cytokines specific for a Th1 IFNγ induced immune response. Immunohistochemical 
staining also showed a significant T-cell response, with pronounced infiltrates of 
CD4+ T helper cells, CD8+ cytotoxic T cells and FOXP3+ regulatory T cells. In addition, 
we found that BIC/microRNA-155 (miR-155) – a microRNA involved in regulation of 
the immune response – was significantly upregulated in lichen sclerosus and lichen 
planus. Furthermore, 34/106 (32%) of the women with lichen planus and 6/42 (14%) 
of the women with lichen sclerosus had a positive titer for serum autoantibodies. 
Taken together, these data demonstrate an autoimmune phenotype in vulvar lichen 
sclerosus and lichen planus, characterized by increased levels of proinflammatory 
cytokines and BIC/miR-155. 
In Chapter 8, the main findings of this thesis are discussed and related to current 
and future research perspectives about treatment of premalignant vulvar and vaginal 
disorders.
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Vulvaire en vaginale premaligne afwijkingen hebben een grote impact op het 
psychoseksueel functioneren. Vrouwen met vulvaire premaligne afwijkingen, 
zoals vulvaire intraepitheliale neoplasie (VIN), hebben vaak ernstige en langdurige 
klachten, en daarnaast is de behandeling gecompliceerd. In het verleden had 
operatieve behandeling de voorkeur, maar de recidiefkans is groot. Daarnaast kan 
een operatie de vulva mutileren, hetgeen gepaard gaat met seksueel disfunctioneren 
en psychosomatische stress. Ook operatieve behandeling van premaligne vaginale 
aandoeningen kan leiden tot seksueel disfunctioneren.
In de afgelopen jaren zijn er verscheidene studies geïnitieerd waarin alternatieve 
behandelingen werden onderzocht, zoals lokale behandeling in de vorm van een 
crème die door de patiënt zelf kan worden aangebracht. Deze nieuwe behandelingen 
hebben als doel om de afweer van de patiënt te beïnvloeden en daarmee het 
onderliggende proces van de premaligne afwijkingen – namelijk een infectie met 
het humaan papillomavirus (HPV) – te bestrijden. Een ander groot voordeel van deze 
behandelingen is dat ze de vulva niet mutileren.
Het doel van dit proefschrift was om de immuunregulatie in premaligne vulvaire 
en vaginale aandoeningen te onderzoeken, waarbij wij ons in het bijzonder hebben 
geconcentreerd op de klinische en immunologische effecten van behandeling met de 
immunomodulator imiquimod.
hoofdstuk 1 geeft een algemene inleiding over de vulva, het afweersysteem en 
de premaligne vulvaire afwijkingen VIN, lichen	sclerosus en lichen	planus.
In hoofdstuk 2 wordt een uitgebreid overzicht gegeven van VIN, de vulvaire	
ziekte	van	Paget en melanoma	in	situ. VIN wordt steeds vaker en op jongere leeftijd 
gediagnosticeerd. De vulvaire ziekte van Paget en melanoma in situ zijn beiden relatief 
zeldzame aandoeningen. Toch is het – vanwege hun kans op maligne ontaarding 
– belangrijk dat vulvaspecialisten bekend zijn met deze diagnoses en de optimale 
behandeling van deze ziekten.
Usual	 type VIN (uVIN) wordt veroorzaakt door een persisterende infectie 
met het humaan papillomavirus (HPV). Een onvoldoende effectieve afweer 
tegen de HPV infectie speelt een belangrijke rol in de etiologie van uVIN. 
Imiquimod is een immunomodulator die de cellulaire afweer activeert. Derhalve is 
onderzocht of imiquimod een effectieve behandeling is voor uVIN. Uit een recent 
placebogecontroleerd, dubbelblind, gerandomiseerd onderzoek (RCT) van onze 
onderzoeksgroep (van Seters et	al.), bleek dat 35% van de patiënten een complete 
respons had na imiquimod behandeling en 46% een partiële respons. Alle ‘complete 
responders’ waren na 1 jaar nog steeds ziektevrij. Het effect op lange termijn was 
tot nu toe echter nog niet bekend. Daarom hebben wij het lange termijn effect van 
imiquimod als behandeling voor uVIN onderzocht, zoals beschreven in hoofdstuk 3. 
Vierentwintig van de 26 patiënten die behandeld werden met imiquimod tijdens de 
eerdere RCT, kwamen voor een follow-up bezoek. De mediane follow-up periode was 
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7.2 jaar. Een recidief trad op in 1 van de 9 complete responders. Daarnaast hadden 
twee van de partiële responders een complete remissie van de restafwijkingen na 
een additionele imiquimod behandeling. Alle andere partiële responders hadden 
tenminste één recidief na de eerdere RCT. 
Tevens bleek dat in complete responders de grootte van de uVIN laesie voor start 
van de RCT kleiner was en dat deze patiënten een betere score op kwaliteit van 
leven hadden tijdens de follow-up, dan de patiënten die nog een restafwijking en/
of recidief hadden. Onze data laten dan ook zien dat behandeling van uVIN met 
imiquimod effectief is op de lange termijn. Omdat kleine laesies eerder volledig lijken 
te reageren op imiquimod dan grotere laesies, is de behandelperiode mogelijk te 
kort geweest om effectief te zijn voor de grotere laesies. Daarom adviseren wij te 
behandelen totdat de afwijkingen niet meer verder in regressie gaan. 
hoofdstuk 4 beschrijft verschillen in het aantal immuuncellen en in de expressie 
van p16INK4a (een marker specifiek voor de aanwezigheid van hoog-risico type HPV) in 
uVIN weefsel voor en na imiquimod behandeling in relatie tot HPV klaring en klinische 
respons. We hebben gekeken naar het aantal immuuncellen en naar p16INK4a expressie 
in de huid van gezonde controles, in de huid van uVIN patiënten die HPV klaarden 
en in de huid van uVIN patiënten die HPV niet klaarden na imiquimod behandeling. 
Vóór de behandeling was er sprake van een verhoogd aantal immuuncellen in zowel 
patiënten die HPV klaarden als patiënten die HPV niet konden klaren in vergelijking met 
gezonde controles. Echter, na de behandeling normaliseerde het aantal immuuncellen 
en p16INK4a expressie in patiënten die HPV hadden geklaard en histologische regressie 
toonden, maar niet in patiënten bij wie HPV nog steeds aanwezig was. Hieruit 
kunnen we concluderen dat HPV klaring geïnduceerd door imiquimod resulteert in 
normalisatie van het aantal immuuncellen, en sterk is gecorreleerd met histologische 
regressie van uVIN.
Sinds is aangetoond dat imiquimod effectief is als behandeling voor uVIN, is 
imiquimod de eerstelijns behandeling voor uVIN in Nederland. Behandeling met 
imiquimod wordt echter niet altijd goed verdragen vanwege de vaak voorkomende 
bijwerkingen als lokale ontsteking, jeuk of branderigheid, koortsachtige symptomen, 
vermoeidheid en hoofdpijn. Wij bemerkten dan ook dat patiënten vaak niet-
steroïde ontstekingsremmende pijnstillers (NSAID’s) of paracetamol gebruiken tijdens 
imiquimod behandeling om deze bijwerkingen te verminderen. Het effect van NSAID-
gebruik tijdens imiquimod behandeling was echter tot nu toe onbekend. Daarom 
beschrijven wij in hoofdstuk 5 of gebruik van NSAID’s, waarvan bekend is dat het 
de cellulaire afweer remt, de uitkomst van imiquimod behandeling beïnvloedt en dus 
ingrijpt op de immuunmodulerende werking van imiquimod. Met een in	vitro studie 
naar het effect van NSAID’s op dendritische cellen (DCs) en Langerhans cellen (LCs), 
laten we zien dat NSAID’s geen effect hebben op het vermogen van DCs en LCs om 
T-cellen te stimuleren of op de productie van cytokines, ondanks dat er wel effecten 
van NSAID’s werden gezien op de expressie van zogeheten DC- en LC- maturation	
markers. In overeenstemming hiermee had frequent NSAID-gebruik ook geen effect 
op de klinische uitkomst na imiquimod behandeling. Deze resultaten impliceren dat 
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NSAID-gebruik geen effect heeft op de functie van DCs en LCs en evenmin ingrijpt 
op de immuunmodulerende eigenschappen van imiquimod in patiënten met uVIN. 
Daarom kunnen NSAID’s veilig gebruikt worden tijdens imiquimod behandeling ter 
vermindering van bijwerkingen.
hoofdstuk 6 beschrijft de effectiviteit van imiquimod als behandeling voor 
vaginale intraepitheliale neoplasie (VAIN), een ziekte die ook wordt veroorzaakt door 
een persisterende HPV infectie. In een pilot studie hebben wij veertien patiënten met 
VAIN tweemaal per week behandeld met imiquimod gedurende 16 weken. Twaalf van 
de 14 patiënten volbrachten de gehele behandeling, twee patiënten stopten vanwege 
hevige bijwerkingen. Drie van de 9 patiënten (33%) waarvan weefsel beschikbaar 
was na behandeling, bleken een complete histologische respons te hebben, en drie 
patiënten (33%) hadden een partiële regressie van de VAIN laesies. Tevens had één van 
de drie patiënten van wie alleen cytologie beschikbaar was na behandeling, normale 
cytologie (PAP1) en toonde een andere patiënt een partiële cytologische respons. 
Daarnaast had roken een negatief effect op de respons na imiquimod behandeling. 
Deze pilot studie laat zien dat imiquimod ook een effectieve behandeling kan zijn 
voor patiënten met VAIN, met name voor patiënten met multifocale afwijkingen of 
waarbij chirurgie niet het middel van eerste keus is. Vanwege mogelijke bijwerkingen 
is het wel van belang dat patiënten voor de behandeling goed worden geïnstrueerd, 
en intensief worden begeleid tijdens de behandeling.
In hoofdstuk 7 zijn de moleculaire en immunologische mechanismen in vulvaire 
lichen sclerosus en lichen planus onderzocht om zo de pathogenese van beide ziekten 
verder te kunnen ophelderen. Met behulp van genexpressie profielen en RT-PCR 
experimenten zagen wij een verhoogde expressie van pro-inflammatoire cytokines 
specifiek voor een Th1 INFγ geïnduceerde afweer. Immunohistochemische kleuringen 
toonden ook een sterke T-celgemedieerde afweer, met een omvangrijk infiltraat 
van CD4+ T helper cellen, CD8+ cytotoxische T-cellen en FOXP3+ regulatoire T-cellen. 
Tevens vonden we in lichen sclerosus en lichen planus een significant verhoogde 
expressie van BIC/microRNA-155 (miR-155) – een microRNA dat betrokken is bij de 
regulatie van de afweer. Daarnaast hadden 34/106 (32%) van de vrouwen met lichen 
planus en 6/42 (14%) van de vrouwen met lichen sclerosus een positieve titer voor 
autoantistoffen. Samenvattend vormen deze data sterke aanwijzingen dat er sprake 
is van een auto-immuun fenotype in vulvaire lichen sclerosus en lichen planus. 
In hoofdstuk 8 worden de belangrijkste bevindingen van dit proefschrift 
besproken en gerelateerd aan de huidige en toekomstige onderzoeksmogelijkheden 
ter behandeling van premaligne vulvaire en vaginale aandoeningen.
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ALA  aminolevulinic acid
ANA  antinuclear antibody
Anti-Tg  antithyroglobulin antibody
Anti-TPO antithyroid peroxidase antibody
APC  antigen presenting cell
Asa  aspirin
ASCUS  atypical squamous cells of undetermined significance
BMZ  basement membrane zone
BSA  bovine serum albumin
CFSE  carboxyfluorescein succinimidyl ester 
CIN  cervical intraepithelial neoplasia 
COX  cyclooxygenase 
CR  complete response
DAB  diaminobenzidine
DAPI  4',6-diamidino-2-phenylindole
DC  dendritic cell
mDC   myeloid dendritic cell 
moDC  monocyte-derived dendritic cell 
pDC  plasmacytoid dendritic cell 
DES  diethylstilbestrol
EGWs  external genital warts
EMPD  extramammary Paget’s disease
EORTC  European Organization for Research and Treatment of Cancer
FACS  fluorescence-activated cell sorting 
FDR  false discovery rate
FSC  forward scatter 
HIV  human immunodeficiency virus
HPV   human papillomavirus
hrHPV  high-risk human papillomavirus 
lrHPV  low-risk human papillomavirus
HRP  horse radish peroxidase
HSIL  high-grade squamous intraepithelial lesion
Ibu  ibuprofen 
IFN   interferon
IL  interleukin
ISSVD  International Society for the Study of Vulvovaginal Disease
LC  langerhans cell
moLC  monocyte-derived langerhans cell
LLETZ  large loop excision of the transformation zone
LP  lichen planus
LS  lichen sclerosus
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LSIL  low-grade squamous intraepithelial lesion
MCP-1  monocyte-chemoattractant protein-1
MHC   major histocompatibility complex
miR  microRNA
MIS  melanoma in situ
MLR  mixed lymphocyte reaction 
NF-κB  nuclear factor-kappa B 
NK  natural killer 
NSAIDs  nonsteroidal anti-inflammatory drugs
NR  no response
PAMP  pathogen associated molecular pattern
PBMC  peripheral blood mononuclear cell  
PBS  phosphate buffered saline
PDT  photodynamic therapy 
PGs  prostaglandins
PGE2  prostaglandin E2 
PR  partial response
QoL  quality of life
RCT  randomized controlled trial
SAM  significant analysis of microarrays
SCC  squamous cell carcinoma
SLE  systemic lupus erythematosus
SSC  sideward scatter 
Th  T helper
TLR   Toll-like receptor 
TNF  tumor necrosis factor
Treg  T-regulatory 
VAIN  vaginal intraepithelial neoplasia
VIN  vulvar intraepithelial neoplasia
dVIN  differentiated	type vulvar intraepithelial neoplasia
uVIN  usual	type	vulvar intraepithelial neoplasia.
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Wladimiroff Research day, Erasmus MC, Rotterdam (oral)
European Academy of Dermatology and Venereology (EADV), Cavtat, 
Croatia (oral)
European College for the Study of Vulval Disease (ECSVD), Munich, 
Germany (oral)
Wladimiroff Research day, Erasmus MC, Rotterdam (oral)
2009
2009
2010
2010
2010
2010
2011
2
0.3
1
1
2
2
1
national and international seminars and workshops
Symposium Nederlandse Vereniging voor Vulvapathologie (NVvVP)
Symposium NVvVP
Erasmus MC PhD Day 
Postgraduate (ECSVD)
Symposium “Vulvaire (pre-) maligniteiten: goed bekeken!”, UMC St 
Radboud, Nijmegen
Attending and presenting in monthly SGGO meetings 
Attending and presenting in weekly research meetings
2008
2009
2009
2010
2010
2008-2010
2008-2011
0.3
0.3
0.3
0.3
0.3
1
2
grant applications, reviewing papers
Reviewing paper for Current HIV research
Reviewing paper for The Australian and New Zealand Journal of Obstetrics 
and Gynaecology
Travelgrant: Erasmus Trustfonds
2011
2010
2010
0.3
0.3
0.3
teaching activities
Teaching students and residents in outpatient vulvar clinic 2009-2010 2 
other
Board member ‘Nederlandse Vereniging voor Vulvapathologie’ 2009-onwards 10
&
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Alweer drie jaar geleden begon ik aan dit onderzoeksavontuur, wat heeft geresulteerd 
in het boekje dat hier voor u ligt. Maar dit boekje had ik in mijn eentje niet kunnen 
maken; velen hebben bijgedragen aan de totstandkoming. Zonder de geweldige 
begeleiding, fijne samenwerking, steun en gezelligheid van collega’s, zou ik niet met 
zoveel plezier op deze inspirerende tijd terugkijken. Ik heb veel geleerd en ben daar 
dankbaar voor. Een aantal wil ik hier persoonlijk bedanken.
Beste professor Helmerhorst, allereerst wil ik u bedanken voor de mogelijkheid om 
bij u onderzoek te doen. Ondanks uw drukke agenda bent u altijd nauw betrokken 
geweest bij het onderzoek. Tijdens het wekelijkse vulvaspreekuur heb ik veel van u 
geleerd, en daarnaast was er dan ook altijd wel een moment om de voortgang van 
het onderzoek te bespreken. Met uw kritische blik wist u altijd het onderzoek een 
stap verder te brengen en nieuwe ideeën te genereren. Dank voor het vertrouwen 
dat u mij hebt gegeven.
Beste Leen, het is een voorrecht om jou als co-promotor te mogen hebben. Vanaf de 
eerste dag wist jij wat voor begeleiding ik nodig had. Je bent er altijd wanneer nodig, 
maar kent ook de kunst van het vrijlaten. Ik kan niets anders zeggen dan dank voor 
de geweldige tijd!
Beste Marc, om tot iets te komen moet je allereerst de kans krijgen, en die kansen 
heb jij mij meer dan eens gegeven. Eerst als keuzeco in het AvL, later als onderzoeker 
bij het VIN-onderzoek, en daarna ook als bestuurslid van de NVvVP. Ik heb veel 
geleerd van je gedrevenheid en positieve instelling. Ondanks hectische tijden ben je 
altijd betrokken geweest bij het onderzoek, maar ook bij mijn keuzes in mijn carrière. 
Dank! 
De leescommissie, professor Hooijkaas, professor Massuger en professor Prens, wil ik 
bedanken voor hun deskundige beoordeling van mijn proefschrift.
Lindy, als partner in crime	 wil ik jou bedanken voor de tijd die we samen aan 
onze onderzoeken hebben gewerkt. De dagen dat we samen onderzoek deden, 
besprekingen voorbereidden en ideeën uitwisselden, waren altijd net dat beetje leuker 
en gezelliger, wat ook motiverend werkte! Ik heb veel geleerd van jouw nuchtere en 
relaxte instelling, en heldere kijk op de zaken. Wat mooi dat we (bijna) tegelijk onze 
onderzoekstijd kunnen afsluiten met onze promoties. 
Alle co-auteurs wil ik bedanken voor de fijne samenwerking en hun bijdrage aan de 
verschillende artikelen.
In het bijzonder Ilse Beckmann voor al het ‘voorwerk’ en grondige revisies van 
het viral clearance paper. Daarnaast wil ik de VIN-onderzoeksgroep bedanken: Beth 
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Morrel, Alex Kleinjan, Wim van der Meijden, Manon van Seters en Patricia Ewing. 
Met veel plezier kijk ik terug op de gezamenlijke donderdag-besprekingen. Met ieder 
zijn eigen input kwamen er altijd nieuwe ideeën naar voren, en dat werkte enorm 
motiverend. Van jullie allen heb ik ontzettend veel geleerd: Alex, door jouw kennis 
van de immunologie en ideeën voor nieuwe experimenten, heb ik me snel wegwijs 
kunnen maken in de wereld van de immunologie. 
Patricia, ondanks alle werkdrukte kon je altijd een moment vinden om samen naar 
coupes te kijken. Dank voor jouw oprechte aandacht en belangstelling, en de goede 
revisies van mijn manuscripten!
Wim, ik heb erg veel geleerd van de eerste weken meelopen met jouw vulvapoli 
en later de goede begeleiding tijdens het wekelijkse vulvaspreekuur. Dank hiervoor.
Beth, je was een welkome aanvulling in de groep en ik bewonder je lef om naast 
een druk werk- en gezinsleven nog een onderzoek op te zetten. 
Manon, pionier van het Rotterdamse VIN onderzoek. Ik zie het als een voorrecht 
dat ik naast Lindy jouw onderzoek heb mogen voortzetten. Meer dan eens heb ik 
vol bewondering gekeken hoe goed jij de dingen georganiseerd had, zodanig dat 
het ook voor mij als nieuweling te begrijpen was. Ondanks alle drukte heb je vanaf 
het begin steeds tijd voor mijn vragen gehad en ik kijk met veel plezier terug op de 
gezamenlijke congressen, vergaderingen en besprekingen. 
De Gynecon-groep: Yongyi, Paul, Marten, Liesbeth en Claudia. Dank voor jullie 
input tijdens de wekelijkse besprekingen. In het bijzonder wil ik Claudia en Liesbeth 
bedanken voor hun hulp bij de experimenten. Beste Claudia, uren heb ik naast jou 
gezeten om te pipetteren, kleuren, kweken, FACSen. Af en toe moet ik wel je geduld 
als nauwkeurige analist op de proef hebben gesteld als ik een domme fout had 
gemaakt of iets niet nauwkeurig genoeg deed. Maar daar was nooit wat van te 
merken: met engelengeduld heb je me alles geleerd en daarnaast is het wachten 
tussen de experimenten toch veel gezelliger met z’n tweeën. Liesbeth, ook jij dank 
voor je inzet en gezelligheid! 
Bestuursgenoten van de NVvVP: Colette, Tom, Hester, Marjo, Bram, Marc, Manon en 
Wim. Dank voor de mogelijkheid die jullie mij geboden hebben om deel te nemen aan 
het NVvVP-bestuur, en daarmee mijn horizon te verbreden binnen de vulvapathologie. 
Colette, ik wil jou in het bijzonder bedanken voor het warme welkom dat je me hebt 
gegeven. Jouw nimmer aflatende enthousiasme om dingen te organiseren werkt 
enorm aanstekelijk! Daarnaast wil ik Tom in het bijzonder bedanken voor zijn hulp bij 
het verwezenlijken van mijn volgende stap: dermatoloog worden. 
Lieve onderzoekers van HS-508, het is een voorrecht om met jullie een kamer te 
hebben mogen delen! Als groentje begonnen bij Lindy, Sharon, Mariëlle en Olivier 
voelde ik me vanaf dag één al thuis. Komende vanuit de kliniek waar weinig tijd 
was voor pauze, moest ik wennen aan de tijd voor lunches en ‘koffiebar-koffie’, 
maar dit maakte dat ik me snel thuis voelde. Onderzoek saai? Nooit in HS-508! 
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De gezelligheid, later ook met Yvonne en Wendy, jullie steun en luisterend oor (niet 
zozeer bij onderzoeksfrustraties, maar vooral heel veel oog- en verhuisfrustraties 
hebben jullie van me moeten aanhoren), de koekela-momentjes als er weer wat te 
vieren was, de ‘lekkere’ koffies, maar ook momenten van samen hard werken, maakt 
dat ik met heel veel plezier terugkijk op de afgelopen tijd. Ik ga jullie heel erg missen!
Ook alle andere onderzoekers wil ik bedanken voor de gezelligheid zowel tijdens 
als na werktijd. 
Alle collega’s van de afdeling Dermatologie van het VUmc wil ik bedanken voor 
hun warme ontvangst waardoor ik met veel plezier begonnen ben aan de opleiding 
dermatologie.
Lieve Fleur, alweer 10 jaar vriendschap. Vanaf het eerste moment was jij mijn beste 
maatje in Groningen. Aan een half woord hebben we genoeg, maar we kunnen 
uren samen filosoferen. Zoals zo vaak gezegd: onze studententijd zou er heel anders 
uit hebben gezien als we elkaar niet hadden gekend. Ook de herinneringen aan 
de tijd in Baltimore is gekleurd met onze mooie, vrolijke, gezellige ondernemingen. 
Met jouw ondernemendheid, doorzettingsvermogen en levenslust weet je overal iets 
moois van te maken. Ik bewonder je kracht om anderen ervan mee te kunnen laten 
genieten. Maar meer dan ook belangrijk dat we elkaar kunnen steunen in mindere 
tijden. Lieve Fleur, je bent een vriendin uit duizenden en voor mij was het dan ook 
meer dan vanzelfsprekend dat je vandaag naast me zou staan. Op nog vele jaren 
mooie vriendschap!
Lieve Ruben, grote kleine broer. Wat ben ik blij dat we (weer) bij elkaar in de buurt 
wonen. Zeker het afgelopen jaar heeft meer dan ook laten zien hoe dicht we bij 
elkaar staan. Ik ben blij met je steun en ben een supertrotse zus! Wat jij doet en 
bereikt, inspireert ook mij weer om het beste naar boven te halen. Als broertje in het 
vak, kan het natuurlijk niet anders dan dat je vandaag naast me staat.
Lieve vrienden en familie. Dank voor jullie interesse in mijn onderzoek, jullie steun en 
daarnaast de momenten van ontspanning buiten werktijd: ik geniet van de gezellige 
borrels, feestjes, etentjes, het samen leuke dingen doen. Dat nog vele mooie 
momenten mogen volgen! 
Lieve broers en zus; Merijn, Ar en Ruub. Ondanks dat we allemaal een hele andere 
weg zijn ingeslagen, ben ik blij dat we zo betrokken zijn bij elkaars doen en laten. 
Jullie zijn er als het erop aankomt, bedankt!
Lieve oma, eigenlijk begon het allemaal op Terschelling in mei 2008. Tijdens een 
heerlijk weekendje bijkomen bij u, kreeg ik het telefoontje dat ik kon solliciteren in 
Rotterdam. Ik ben zo blij dat u de afgelopen jaren dit heeft meegemaakt. Al van 
jongs af aan zijn opa en u er altijd voor ons geweest. Uw interesse, steun en liefde en 
de dagen of avondjes dat ik bij u kwam vanuit Rotterdam, zijn voor mij heel bijzonder 
en zal ik nooit vergeten. 
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Lieve Ben, lieve mama. De basis die jullie als ouders hebben gegeven, heeft 
gemaakt dat ik altijd in mezelf heb kunnen geloven. Jullie steun in alles wat wij 
ondernemen en de keuzes die we maken, vind ik heel bijzonder. Ik kan alleen maar 
hopen dat ik dat later ook kan! Dank jullie wel. 
Lieve Willem, je onvoorwaardelijke steun, liefde en zorgzaamheid maken dat ik bij 
jou rust vind. Samen bikkelen en samen genieten; met jou lijkt het dat ik daar toch 
(eindelijk) een balans in heb gevonden..
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aBout the author
Annelinde Terlou (18 november 1982) attended secondary school at the Christelijk 
Gymnasium Utrecht, combining regular schooling with an early career as violinist at 
the Young Talent Class of the Utrecht Conservatory (1993-2001). After graduation she 
studied Medicine at the Rijksuniversiteit Groningen. Highlights during her study were 
internships at Hospital Sao João, Porto, Portugal and at the Antoni van Leeuwenhoek 
Hospital in Amsterdam under supervision of Dr. M. van Beurden; under supervision 
of Prof. dr. P.C. Rowe and Prof. dr. C.L. Schwartz she carried out a research project 
at the Department of Pediatric Oncology at the Johns Hopkins University School of 
Medicine in Baltimore. This project resulted in her first international publication.
After graduation (cum laude) in 2007, Annelinde worked during 6 months as 
a resident at the Department of Obstetrics and Gynecology at the St. Antonius 
Hospital in Nieuwegein, followed by a PhD project on premalignant vulvar and vaginal 
disorders at the department of Obstetrics and Gynecology at the Erasmus University 
Medical Center in Rotterdam under supervision of Prof. dr. Th. J. M. Helmerhorst. 
During her PhD project she presented her work at different national and international 
conferences, and was awarded with the ‘best candidate presentation’ at the 20th 
conference of the International Society for the Study of Vulvar Disease (ISSVD). 
She combined her PhD project with work as a clinician at the Vulvar Outpatient 
Clinic of the Erasmus University Medical Center, and became a board member of 
the ‘Nederlandse Vereniging voor Vulvapathologie’ (NVvVP).
During her clinical work at the Vulvar Outpatient clinic, she became interested 
in Dermatology. Therefore, she has started in September 2011 her residency 
in Dermatology at the VU medical center in Amsterdam under supervision of 
Prof. dr. Th.M. Starink. 


